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The aim of the following narrative review is to examine the current evidence 
for cardiovascular changes in pregnancy, and for the differences between 
cardiac function in morbidly obese and non-obese non-pregnant individuals. 
Echocardiographic findings in the hearts of non-pregnant obese subjects are 
discussed in depth, exploring advances in functional measurement 
techniques. The utility of echocardiography in the clinical management of the 
parturient is also briefly outlined, including the limited data available on the 
obese parturient. 
 
2. Literature Search Strategy 
All publications relevant to the subject were obtained online, from the 
University of Cape Town Health Science Library search facility. This includes 
resources from 17 medical digital archive databases worldwide. Literature 
published up to- and including the year 2017 was included. In total, 51 relevant 
papers were identified. Literature not published in the English language was 
excluded.   
 
3. Quality Criteria 
Keywords and phrases used in the search, in various combinations, included: 
obesity, pregnancy, cardiac function, diastolic dysfunction, transthoracic 
echocardiography and tissue Doppler.  
 
4. Summary of the Literature 
a.  Introduction 
Obesity is an ever-increasing global health issue. Previously predominantly a 
disease of the developed world, lower- and middle-income countries have 
displayed alarming increases in the proportion of overweight and obese 




weight status according to body mass index (BMI) as follows:  
• Underweight: BMI < 18.5 kg/m2, 
• Normal weight: BMI 18.5 - 24.9 kg/m2,  
• Overweight: BMI 25.0 - 29.9 kg/m2, and  
• Obesity: BMI > 30 kg/m2.  
Obesity is subdivided into class I (30.0 - 34.9 kg/m2), class II (35.0 - 39.9 
kg/m2), and class III (>40 kg/m2), with any BMI above 35 equating to morbid 
obesity.1 In 2013, South Africa was ranked the country with the third highest 
incidence of obesity, behind only the United States of America and Mexico. 
The prevalence of overweight and obesity, as defined above, in South African 
women more than 20 years old is 69.3%, while 26.3% of women below 20 
years fall into the same categories. Forty two percent of women above the age 
of 20 years and 9.6% of below 20 years are considered obese.2 
In 2010, 44% of parturients attending an antenatal clinic in South Africa were 
classified as obese or morbidly obese.3  These patients were found to be at 
significantly increased risk of urinary tract infections and gestational diabetes 
mellitus, and more often needed induction of labour and longitudinal skin 
incision at caesarean section (CS).3 The adverse effects of obesity in 
pregnancy are well documented in numerous studies and include, but are not 
limited to, increased rates of CS4 and difficult neuraxial anaesthesia5. This is 
of particular relevance to anaesthesia practice. Obese women are also at 
higher risk of early pregnancy losses,6 postpartum haemorrhage, surgical site 
infections and venous thromboembolic disease.7  
Whilst many studies have suggested an increased association with gestational 
hypertension, preeclampsia and cardiovascular disease in obese pregnant 
women,4 little is known about the long-term sequelae. A large cohort study 
published in 2015 followed up more than 18 000 women who were admitted 
with a major cardiovascular event, up to 50 years post-delivery of their first 
child. The authors concluded that maternal overweight and obesity were 





b. Cardiovascular and haemodynamic changes in uncomplicated 
pregnancy 
The maternal cardiovascular adaptations to pregnancy are numerous and well 
documented. From as early as 5 weeks’ gestation, systemic vascular 
resistance (SVR) decreases, with a compensatory increase in maternal heart 
rate.9,10  The increase in heart rate is initially responsible for the observed 
increase in cardiac output (CO) during pregnancy. Further CO increases are 
attributable to a greater stroke volume (SV) as pregnancy progresses.9 
Systolic, mean and diastolic blood pressure all decrease during pregnancy, 
with the lowest values recorded in the second trimester. Thereafter there is an 
increase in blood pressure to pre-pregnancy levels at term.9,10  The total blood 
volume increases from the 6th week of gestation to 40% above pre-conception 
levels by term, which in turn leads to an increase in preload.9,11-13 An increase 
in the compliance of the arterial and venous systems allows for 
accommodation of the increased plasma volume.11  
The structural changes which occur in response to the above-mentioned 
volume-loaded state have been studied by echocardiography since as early 
as 1979.13 There is consensus in the literature that the left atrium (LA) displays 
a gradual and continuous, significant increase in size in response to the 
physiological state of volume overload.12-14 The changes of the left ventricle 
(LV) are less consistent, with some authors reporting a definite increase in left 
ventricular end-diastolic dimensions, whilst others reported no observed 
change.11,12,14 A study by Simmons et al15 demonstrated echocardiographic 
evidence of left ventricular hypertrophy (LVH), which was directly related to 
the increased work-load imposed on the heart during pregnancy. The mean 
increase in LV wall thickness of 11% was in keeping with numbers reported in 
other studies.11,15,16 The increase in left ventricular mass (LVM) was noted in 
some studies to be in excess of the increase in body size11,15 indicating a true 
hypertrophic response. When indexed to the ventricular diastolic volume in a 




between the second and third trimesters. The authors suggested that an 
eccentric rather than concentric pattern of hypertrophy was present in the 
ventricle.  
The reported changes in LV systolic function, measured as LV ejection fraction 
(LVEF) and fractional shortening (FS), are varied across the literature. The 
variability in results may be due to the measurement methods used in older 
studies. Where LV ejection fraction is calculated using the Teicholz formula, 
measurements cannot be assumed to be accurate.16 This formula presumes 
certain geometric norms which are no longer present in pregnancy, due to the 
changes in left ventricular wall thickness and shape which have been 
described previously. Studies using the Teicholz formula and M-mode imaging 
modalities for the quantification of ejection fraction tended to report an initial 
increase in LV systolic function up to the end of the second trimester, and a 
subsequent decrease in ejection fraction toward term. Despite the observed 
decrease, CO still remained higher than pre-pregnancy levels.16,17 Data from 
newer studies, employing more modern echocardiography techniques, have 
produced results which contradict the notion that CO decreases at term. 
Simmons et al found that both fractional shortening and rate-adjusted mean 
velocity of circumferential fibre thickening were increased up to- and including 
the third trimester. When corrected for the abnormal loading conditions of 
pregnancy, load-adjusted indices of myocardial contractility were still normal, 
suggesting that contractility is unaffected.15  
Diastolic function has not been shown to change significantly in normal 
pregnancy.13-15 The increase in plasma volume, and subsequently preload, 
leads to an expectedly high trans-mitral inflow velocity (E), but no change in 
the conventional measurement for diastolic dysfunction (E/A ratio) was 
noted.13  
Although the physiological changes associated with pregnancy have been 
thoroughly studied, quantifying these changes in a meaningful way with 






c. Cardiac structure and function in the non-pregnant obese population 
The changes in cardiac structure and function caused by obesity have been 
extensively studied and documented.18-20 There is good evidence that obesity 
is associated with the development of hypertension, hyperlipidaemia and 
diabetes, as well being an independent risk factor for the development of 
congestive cardiac failure.21,22 
The commonly encountered changes are: 
i. Left ventricular remodelling: 
The left ventricular mass has been shown to be significantly increased in 
obese subjects.18,19,23-26 The clinically accepted method to measure LVM by 
echocardiography is the formula suggested by Devereux, which states that 
LVM = 0.8{1.04[([LVEDD + IVSd + PWd]3 – LVEDD3)]} + 0.6, where LVEDD 
is the left ventricular end-diastolic diameter, IVSd is the thickness of the 
interventricular septum in diastole and PWd is the posterior wall thickness in 
diastole.27 Indexing of LVM in obesity is a controversial issue in the literature. 
The DuBois formula for calculating body surface area has been shown to be 
inaccurate in patients with a weight greater than 150 kilograms27 and the 
increase in body surface area (BSA) in these patients is greater than the 
increase in LVM, often leading to a falsely normal or low measurement of left 
ventricular mass index (LVMI). Normalisation of LVM to height or to height to 
the power of 2.7 has been shown to be a more appropriate method of indexing 
in this population. One study identified significantly higher values of LVM 
indexed to height2.7 in their obese study population than in normal weight 
controls, a finding which was absent when indexing was  to BSA in the same 
persons.23 Elevated BMI is a robust predictor of LVH and increases in LVM, 
confirming a definite causal relationship between obesity and hypertrophy, 
even in normotensive subjects.24,25,28 Interestingly, females seem to have a 
greater increase in LVM in response to obesity than men of similar age, degree 





There is no consensus in the literature as to the pattern of hypertrophy noted 
in obese subjects. This is likely due to the differences in age, gender, co-
morbidities and exclusion criteria between studies. The majority of authors 
have reported findings of an eccentric pattern of hypertrophy,23,24,28 whilst 
some others have found the changes to be more in keeping with concentric 
hypertrophy.25,29 Concentric hypertrophy is present when there are increases 
in LVM, LVMI, LV wall thickness and relative wall thickness (RWT) but the LV 
chamber size remains unchanged. Peterson et al28 studied a group of healthy 
young obese women with no other co-morbidities. It is of concern that this 
group displayed concentric remodelling, as this has previously been 
associated with increased cardiovascular morbidity and mortality.30 The 
changes in LV geometry are, however, not permanent and can be reversed 
with weight loss, even if some degree of obesity persists.31  
ii. Right ventricular size 
There is little work published on the changes in right ventricular size as a result 
of obesity. Wong et al found the right ventricle (RV) to be increased in diameter 
and noted an increase in right ventricular wall thickness.32 It has previously 
been suggested that right heart changes in obesity develop as a consequence 
of obstructive sleep apnoea (OSA) and sleep disordered breathing.33 This was 
not found in Wong’s study, where the changes were unrelated to the presence 
or severity of OSA, but did appear to be related to the degree of obesity.32  
iii. Left atrial size 
Left atrial diameter has been found to be consistently enlarged.18,31 This is 
likely due to the increased plasma volume in obesity leading to a state of 
volume overload. Diastolic filling abnormalities, which are addressed in detail 
later in this review, may also contribute to the noted increase. 
iv. Left ventricular systolic function 




blood volume and oxygen demand, with a subsequent increase in CO.26 Both 
preload and afterload have been shown to be increased in obese subjects 
when compared with persons of normal weight.33 Cardiac systolic function in 
obesity has been widely studied, by different methods. There has been 
controversy in the literature since 1981, with a cardiac catheterisation study 
describing impaired systolic function26, whilst others have suggested that 
contractile function is preserved.34 Echocardiography now allows non-invasive 
quantification of LV function by a number of different methods. The LVEF and 
FS as measured by two-dimensional echocardiography, have been shown to 
be preserved, and sometimes augmented, even in severe obesity.35,36 LVEF 
and FS are, however, insensitive methods of determining systolic function. 
They are known to be load-dependent variables, which are unreliable in the 
face of the abnormal physiological loading state in obesity. Subclinical 
changes in systolic function have been detected in young, otherwise healthy, 
obese women using newer echocardiography modalities.28 Tissue Doppler 
Imaging (TDI) measures the velocity of the movement of individual walls of the 
myocardium37 and has been shown to demonstrate subtle dysfunction in 
obese persons, even in the face of a preserved LVEF.19,24,25 A limitation of TDI 
is that it is unable to distinguish myocardial movement due to contraction, from 
passive movement of the myocardium.37 Strain rate imaging, which is less 
affected by passive movement of the myocardium, has also demonstrated a 
global decrease in left ventricular contractility in obesity.24,38  
v. Left ventricular diastolic function 
Diastolic function can be quantified during echocardiography by measuring 
mitral inflow patterns. The ratio between mitral early (E) and atrial (A) velocities 
is a marker of LV relaxation and filling. The mitral E-wave velocity describes 
filling during early diastole, while the A-wave velocity describes the atrial 
component to LV filling. The E-wave deceleration time (DT) and isovolumetric 
relaxation time (IVRT) are also frequently used as surrogates for diastolic 
function.39,40 The changes to mitral inflow velocities noted in obesity are 
consistent in the literature; however, being load-dependent indices, their 




and increase in E-wave deceleration suggest impaired early ventricular filling, 
whilst IVRT, a marker of impaired relaxation, has consistently been found to 
be prolonged in obese subjects.19,27,35,41 These changes have been detected 
in obese children and adolescents who are otherwise healthy, which could 
indicate that diastolic dysfunction occurs very early in obesity and is not related 
to the expected age-related changes in myocardial relaxation.41  
TDI, again, is not influenced by the abnormal loading conditions in obesity, 
and gives a true reflection of diastolic function. Measurements are made at the 
septal and lateral insertion sites of the mitral leaflets, which allows one to 
quantify the velocity and amplitude of excursion of the mitral annulus.39 
Various studies have demonstrated diastolic dysfunction in obese persons 
using TDI.19,28,41 The study populations were, once again, adolescents41 and 
young healthy women28, suggesting that diastolic changes are the first sign of 
cardiac dysfunction in obesity. 
vi. Right ventricular function 
The overlap between obesity and sleep-disordered breathing makes 
quantification of alterations in right ventricular function difficult to interpret. 
OSA has been shown to lead to RV hypertrophy and reduced RV systolic 
function in previous studies.33,43,44 A study by Wong et al32 compared RV 
function in obese and non-obese subjects, all of whom had confirmed OSA 
diagnosed by polysomnography. The authors showed that the systolic and 
diastolic dysfunction correlated positively with the degree of obesity, but was 
not related to the presence of sleep-disordered breathing. These findings were 
confirmed by another group who used TDI to quantify diastolic and systolic RV 
function.38  
 
All of the above-mentioned changes in cardiac structure and function appear 
to be positively correlated with the duration of obesity. Alpert et al45 showed 
significant associations between duration of obesity and increased markers of 
preload and afterload on echocardiography. These alterations in LV loading in 
turn lead to the increased LVMI and impairment of diastolic function described 




surgery have shown that all abnormalities reported show some improvement 
with a decrease in BMI.42,45  
d. Haemodynamics in the obese parturient 
Whilst the issues of haemodynamic adaptations to both pregnancy and obesity 
have been well documented, the changes brought about by the two in 
combination are not as well understood. Three studies have interrogated the 
issue, studying various echocardiographic parameters in obese pregnant 
women. Their study populations are, however, small and definite conclusions 
cannot be firmly drawn.46–48  
Mean arterial pressure (MAP) has been shown to be significantly higher in 
obese pregnant subjects when compared with their non-obese 
counterparts.10,47 Veille et al.48 found that obese parturients had increased 
septal and posterior wall thickness and LVM, but no significant changes in left 
ventricular dimension, FS and cardiac index (CI). Dennis et al47 reported a 
significantly elevated LVM in their obese subjects, but found no differences in 
the degree of systolic or diastolic function measured by TDI. This is in contrast 
with another study which showed that SV and contractility, measured by strain 
indices which eliminated the effects of abnormal loading conditions, decreased 
during the third trimester. The concern in such individuals is that they may not 
be able to mount an adequate cardiovascular response to the haemodynamic 
demands of pregnancy. Load-dependent indices of myocardial function failed 
to detect any differences between obese and non-obese pregnant women, 
suggesting again that these methods are inadequate to assess cardiac 
function in the group of interest.46 Serial transthoracic echocardiography (TTE) 
studies performed on each of the women in the study group showed that 
myocardial performance improved in obese pregnant women post-partum.46  
e. Transthoracic echocardiography as an assessment tool 
TTE is an attractive assessment tool in parturients. It is non-invasive, and 
ultrasound as a modality of evaluation is acceptable to pregnant women as a 
routine aspect of their care. TTE is increasingly becoming an essential 




subspecialties are relying on echocardiography for diagnosis and 
management, especially in the perioperative period.49,50 The diagnosis of 
cardiac disease in pregnancy is challenging as peripheral oedema and 
breathlessness are often seen in this population, even when significant 
underlying disease is absent. Obesity compounds this diagnostic dilemma. 
Dennis and her co-authors were able to obtain acceptable echocardiographic 
images in all of the patients enrolled in their study, even those classified as 
being morbidly obese.47 The parasternal and apical views are easily obtained 
in pregnancy, however performing subcostal views is not recommended in this 
group.47,51 Echocardiography is both feasible and acceptable in the 
assessment of pregnant women.   
 
Conclusion 
Obesity is an ever increasing public health issue and especially affects 
clinicians in the South African context.1–3 Obese parturients are considered 
to be high-risk patients at risk of multiple peri-partum complications.3–7 The 
physiologic changes of the cardiovascular system during pregnancy are well 
understood and documented.9,10 Echocardiography has been used as a 
measure to quantify the adaptation of the heart to these changes in terms of 
morphology and function. Healthy pregnant women frequently display 
changes on echocardiography, including larger left sided chambers and 
increased LVM; however measures of cardiac function have shown varied 
results.11–16  
The additional demands placed on the cardiovascular system by obesity 
result in changes in cardiac structure and function. The combined effect of 
pregnancy and obesity has not been  studied in large cohorts, with only three 
groups publishing small studies describing the echocardiography parameters 
in such individuals.46–48 Echocardiography has been shown to be feasible in 
obese pregnant women47, but this review identifies a need for a larger cohort 
study, to more clearly define structural and functional differences between 
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The increasing prevalence of obesity worldwide is a major threat to global 
health. Structural and functional changes in the heart are well documented 
for obesity as well as for pregnancy, but there is limited literature on the 
impact of obesity on cardiac function in pregnancy. We hypothesized that 
cardiac maladaptation to pregnancy occurs more frequently in otherwise 
healthy morbidly obese pregnant women than in pregnant women of normal 
body mass index (BMI). 
Methods 
This prospective cohort study was performed in two referral maternity units in 
Cape Town, South Africa, over a 3-month period. Forty morbidly obese 
pregnant women (BMI ≥40 kg.m-2) (Group O) were compared to 40 pregnant 
women of BMI 30 kg.m-2 (Group N). Cardiac structure and function were 
assessed by transthoracic echocardiography, according to the 
recommendations of the British Society of Echocardiography. 
Results  
Acceptable echocardiographic images were obtained in all obese women. 
Statistical significance was defined as P< .005 after applying the Bonferroni 
correction for multiple comparisons. Mean [SD] mean arterial pressure was 
higher in Group O (91 [8.42] vs 84 [9.49] mmHg, P<0.001). There were no 
between-group differences in heart rate, cardiac output, or cardiac index (84 
[12] vs 79 [13] beats.min-1, P=0.103; 5447 [1048] vs 4740 [1183] mL.min-1, 
P=0.006; 2551 [474] vs 2729 [623] mL.min-1.m-2, P=0.156, respectively). 




(30.14 [4.51] vs 34.25 [7.00] mL.m-2, P=0.003; 152 [24] vs 115 [29] g, 
P<0.001). Isovolumetric relaxation time was significantly prolonged in Group O 
(73 [15] vs 61 [15] milliseconds, P<0.001). The septal tissue Doppler index E' 
sept was lower in Group O (9.08 [1.69] vs 11.28 [3.18], P<0.001). There were 
no between- group differences in E' average (10.7 [2.3] vs 12.0 [2.7], 
P=0.018), or E/E' average (7.85 [1.77] vs 7.27 [1.68]). 
 
Conclusion  
Obese pregnant women had a similar cardiac output and cardiac index to 
those with normal BMI. Their increased left ventricular mass and lower stroke 
volume index could indicate a limited adaptive reserve. Obese women had 
minor decreases in septal left ventricular tissue Doppler velocity, but the E/E' 














The worldwide epidemic of obesity is a major threat to global health. In 2014, 
the World Health Organisation (WHO) estimated that 39% of the population 
aged ≥18 years were overweight, defined by a body mass index (BMI) of ≥25 
kg.m-2. Thirteen percent had a BMI of ≥30 kg.m-2 and were therefore 
classified as obese.1,2 In the United States, 58.5% of women of childbearing 
age (20-39 years) are overweight and 31.8% are obese.3 Numbers in other 
high and middle income countries are comparable.2 The deleterious health 
effects of obesity are well documented, with most deaths in this population 
attributable to cardiovascular disease.4,5 Structural and functional changes in 
the heart caused by obesity, such as left ventricular hypertrophy, left atrial 
enlargement and subclinical impairment of systolic and diastolic function, are 
well studied in the general population.6 Much less is known about the impact 
of obesity on cardiovascular adaptation to pregnancy. 
In pregnancy, obesity is associated with an increased risk for venous 
thromboembolism, hypertensive disorders, gestational diabetes, caesarean 
section, postpartum haemorrhage and adverse neonatal outcome.7-10 Data 
from both the United Kingdom and the United States demonstrate that 
obesity is associated with an increased risk of death during pregnancy.11-14 A 
large cohort study from Scotland published in 2015 found that maternal 
obesity during pregnancy is associated with major cardiovascular events 




Echocardiography has been used extensively to study cardiovascular 
changes in pregnancy.16-19 However, to our knowledge there have only been 
two small studies assessing haemodynamic changes in obese parturients 
with echocardiography published to date. Dennis et al. studied 15 obese 
pregnant women with a mean BMI of 35 kg/m2, comparing them with 40 
pregnant women of normal weight. A significantly higher mean arterial 
pressure and left ventricular mass were found in the obese parturients.20 
Veille et al. compared 8 morbidly obese pregnant women with 36 parturients 
of normal weight and found an increase in left atrial size, left ventricular wall 
thickness and left ventricular mass in the obese group.21 
As anesthesiologists, we are closely involved in the peripartum care of 
pregnant women. A thorough understanding of the cardiovascular changes 
of pregnancy and how these may be altered in the obese parturient, is crucial 
to deliver optimum care. Transthoracic echocardiography is a valuable non-
invasive tool to study the cardiovascular system. The aim of our research 
was to study structural and functional changes in morbidly obese parturients 
(BMI ≥40 kg.m-2) compared to pregnant women of normal body mass (BMI 
≤30 kg.m-2) at term, using transthoracic echocardiography. We hypothesized 
that there are both cardiac structural and functional differences between term 









This prospective cohort study was conducted at the two referral maternity 
units affiliated to the University of Cape Town, Cape Town, South Africa: 
Mowbray Maternity- and Groote Schuur Hospital. Data collection took place 
from 1st January to 31st March 2016. Due to the limited availability of 
previous data on haemodynamic changes in morbidly obese pregnant 
women, a sample size calculation was not performed. We aimed to recruit at 
least 40 morbidly obese pregnant women (Group O) and 40 pregnant women 
of normal weight as controls (Group N), a sample size used in previous 
similar work.19,22 The data was reported according to the principles of the 
STROBE guidelines. The study protocol was approved by the Human 
Research Ethics Committee of the University of Cape Town (HREC 
021/2016). All participants provided written, informed consent. Obese and 
control parturients were recruited consecutively from the antenatal clinic and 
the antenatal wards at both hospitals. The exclusion criteria were: age below 
18 years, inability to give informed consent, refusal to participate in the study, 
pre-existing cardiac co-morbidities, essential or gestational hypertension, a 
positive HIV status (previous work showed that HIV infection influences 
cardiac structure and function22) and active labour. For both groups, only 
women with singleton pregnancies who had reached at least 36 weeks of 
gestation were recruited. Recruitment to Group O required a BMI of at least 





After enrolment, the following demographic and biological data were 
recorded: age, gravidity, parity, gestational age, ethnicity, height, weight, and 
haemoglobin level. Baseline blood pressure was measured in the sitting 
position after a period of rest. An automated oscillometric blood pressure 
device (Dinamap Carescape, General Electric Corporation, Boston, 
Massachusetts), with an appropriately sized cuff for the respective study 
participant, was used. The heart rate was obtained from a three lead 
electrocardiograph recorded during echocardiography. 
Echocardiography Protocol 
After a 5-minute rest period in the left lateral position, echocardiographic 
examination was performed according to international guidelines using 2-
dimensional color flow-, continuous wave-, pulsed wave- and tissue Doppler 
imaging.23-25 All echocardiographic examinations were conducted by the 
same certified investigator (BSB) using either a Vivid S or a Vivid Q 
echocardiography machine with a 1.5 – 3.6 MHz transducer (General Electric 
Corporation, Boston, Massachusetts). Structural and haemodynamic 
measurements were performed according to standard recommendations.23-25 
Structural parameters [septal (IVSd) and posterior wall thickness (LVPWd) in 
diastole, left ventricular internal diameter in diastole (LVIDd)] and their 
derived parameters [left ventricular mass (LVM) and relative wall thickness 
(RWT)] were obtained from a 2-dimensional parasternal long axis view 
(PLAX). Controversy exists regarding appropriate indexing of left ventricular 




surface area (BSA) is often normal or even reduced, since BSA increases in 
excess of left ventricular mass in obese individuals. Several authors 
therefore prefer to index left ventricular mass either to height alone, or to 
height raised to the power of 2.7.6 Therefore we performed 3 calculations, 
indexing to body surface area, height, and height2.7.  
Left ventricular systolic function was assessed by fractional shortening (FS) 
(derived from a 2-dimensional PLAX view), fractional area change (FAC) 
(measured during systole and diastole from the parasternal short axis image 
at mid-papillary level), and by the systolic tissue Doppler velocity (S'). The 
latter was obtained from an apical 4 chamber view. Stroke volume (SV) and 
cardiac output (CO) were calculated from left ventricular outflow tract (LVOT) 
diameter (measured in the PLAX view), the Doppler-derived velocity time 
integral of the left ventricular outflow tract (LVOT VTI) measured in the apical 
five chamber view, and the heart rate. Cardiac work (CW) and total vascular 
resistance (TVR) were calculated from mean arterial pressure (MAP) and 
cardiac output. Diastolic function was assessed by mitral valve inflow 
velocities E and A, mitral valve deceleration time (DT), isovolumetric 
relaxation time (IVRT) derived from septal tissue Doppler measurements, 
early diastolic tissue Doppler velocity E' (obtained in an apical four chamber 
view) and the ratio of early mitral flow peak velocity to early diastolic tissue 
Doppler velocity (E/E'). Right ventricular systolic function was assessed by 
tricuspid annular plane systolic excursion (TAPSE) and right ventricular 
systolic tissue Doppler velocity (RV S') from the right ventricular free wall 




function was assessed by early and late tissue Doppler velocities of the right 
ventricular free wall (RV E' and RV A', respectively). 
Echocardiography images were stored and analysed off-line by BSB. The 
average value of three consecutive beats for each measurement were used 
for data analysis. A second certified investigator (BC) independently 
measured LVOT, LVOT VTI, FAC and LVIDd of every 5th participant to 
enable inter-observer variability to be calculated. These parameters reflect 
hemodynamics, function and anatomy. 
Statistical Analysis 
Descriptive statistics including frequency, mean, standard deviation, median 
and interquartile range were calculated for the two study groups. The two 
sample t-test with unequal variance was used for the comparison of the 
mean values between the groups. The mean difference between the groups, 
and 95% confidence interval (CI) was reported for the continuous variables. 
The range of BMI was by definition restricted, therefore values are reported 
as median (interquartile range [IQR]). After adjustment for multiple 
comparisons using the Bonferroni correction, p < .005 was considered 
statistically significant. The inter-observer bias was estimated by calculating 
the mean difference and 95% CI between readings recorded by two 







Forty morbidly obese pregnant women (BMI ≥40 kg.m-2) and 45 pregnant 
women of normal weight (BMI ≤30 kg.m-2) were recruited to the study. Data 
was analysed from all of the morbidly obese parturients recruited. None had 
pre-existing cardiac disease and all had acceptable echocardiographic image 
quality. Five subjects in the control group were excluded; three as a result of 
poor echocardiographic image quality, and two due to undiagnosed pre-
existing cardiac conditions. In one woman hypertrophic obstructive 
cardiomyopathy was suspected, and the other had a severe tachyarrhythmia. 
Both women were referred for review by a cardiologist. 
Demographic and obstetric characteristics of both groups are shown in Table 
1. There were no significant between-group differences in age, gestational 
age, ethnicity, gravidity, parity and haemoglobin level. The median BMI of 
Group O was 42.9 kg.m-2 (IQR: 41.3 to 47.1 kg.m-2) versus 27.3 kg.m-2 (IQR: 
24.2 to 29.2 kg.m-2) in Group N. 
Table 2 summarises the haemodynamic findings. MAP was significantly 
higher in Group O (91 vs 84 mmHg). There were no significant between-
group differences in heart rate (HR), stroke volume (SV) and cardiac output 
(CO). The stroke volume index was significantly lower in Group O (34.25 vs 
30.14 mL.m-2) The mean difference (95% CI) was 4.11 mL.m-2 (-6.73 to -
1.47). 
Table 3 shows the results for left ventricular structural and functional 




(0.82 vs 0.66 cm, and 1.07 vs 0.95 cm). The mean difference (95% CI) was 
0.16 (0.11 to 0.22) and 0.12 (0.06 to 0.19) cm respectively. There was no 
significant between-group difference in the RWT and the LVIDd. LVM was 
significantly higher in Group O (152 vs 115g). with a mean difference (95% 
CI) of 37 (25 to 49) g. When indexed to body surface area (BSA), there was 
no significant difference in the left ventricular mass index (71 vs 66 g.m-2). 
Indexing to height and height2.7resulted in significantly higher values for 
Group O (95 vs 71 g.m-1 and 43  vs 32 g.m-2.7 respectively). The mean 
differences (95% CI) for these parameters were 24 (16 to 31) g.m-1 and 11 (8 
to 15) g.m-2.7 respectively. Fractional shortening (FS), fractional area change 
(FAC) and both lateral and septal systolic tissue Doppler velocities were 
comparable between groups. 
Diastolic measurements are summarised in Table 4. Global diastolic function 
was not significantly reduced in Group O. However, septal E' was 
significantly reduced (9.08 vs 11.28 cm.s-1). The mean difference (95% CI) 
was -2.20 (-3.34 to -1.06) cm.s-1. The isovolumetric relaxation time was 
significantly longer in Group O (73 vs 61 ms). The mean difference (95% CI) 
was 12 (6 to 19) ms. 
Table 5 summarises the findings for the right ventricle. There was no 
between-group difference in right ventricular systolic function. RV E'/A' was 
not significantly different between groups. 
Calculation of inter-observer variability showed the following results (mean 
difference [95% CI]): LVOT 0.05 cm [-0.02 to 0.12], LVOT VTI 0.64 cm/s [-





There are limited data available on cardiovascular structure and function as 
assessed by transthoracic echocardiography in morbidly obese pregnant 
women. To our knowledge this is the largest comparative study in this field. 
Previous work studied fewer women of lower BMI.20,21 It is noteworthy that all 
obese patients in our study had acceptable image quality. We found 
differences in LV structure and function when comparing obese parturients 
with those with normal BMI. IVSd and LVPWd, LVM, and LVM indexed to 
height and height2.7, were all significantly increased in the obese population. 
MAP was higher in Group O. Stroke volume index (SVI) was lower in Group 
O, with no significant differences in CO or cardiac index (CI). Fractional 
shortening and septal systolic tissue Doppler velocities were similar in the 2 
Groups. With regard to diastolic parameters, there was a significant increase 
in the IVRT, and septal E' was significantly lower in Group O. There were no 
significant inter-observer differences in the reported measurements for 
LVOT, LVOT VTI, and FAC. The difference for LVIDd was statistically- but 
not clinically significantly different (1.4 mm). It was noted that for certain 
haemodynamic (MAP, but not TVRI), structural (LVM) and functional (IVRT) 
parameters, there appeared to be a correlation across the BMI range. Thus 
the reported differences were not only present at the extremes of the 
biological range represented by the study groups. 
Dennis et al. found a similar increase in left ventricular mass and in the mean 
arterial pressure, but reported no changes in the isovolumetric relaxation 




IVSd, LVPWd and LVM in obese patients, but no significant changes in left 
ventricular dimension, fractional shortening and cardiac index.21 
Echocardiographic studies of cardiovascular changes in obese non-pregnant 
subjects demonstrate similar changes to those we observed in the obese 
pregnant population. In isolated obesity LVM is increased.26,27 Left ventricular 
ejection fraction has been reported as reduced, normal or supranormal.6 
Findings regarding diastolic function are conflicting. The most consistent 
finding is a prolongation of the IVRT.28-30 Two studies reported altered right 
ventricular diastolic filling characteristics, one of which also reported reduced 
systolic tissue Doppler velocities for right-sided chambers. Right ventricular 
ejection fraction was not altered.26,31 
A recently published study by Vinayagam et al. compared hemodynamics of 
30 morbidly obese pregnant women with 32 pregnant women of normal 
weight, using the non-invasive cardiac output monitoring system USCOM®. 
They found a significantly reduced SVI and CI in obese patients, while the 
total vascular resistance index (TVRI) was significantly higher in these 
parturients.32 
Confounding variables were carefully considered in the design phase of this 
study, and clear exclusion criteria were established, importantly hypertension 
and pre-existing cardiac disease. While the lack of any significant differences 
in the patient characteristics do not eliminate confounding variables; it is 
unlikely that there were clinically significant differences in these 




require follow-up postpartum to define more clearly the effects of pregnancy 
versus obesity per se.  
A further limitation of the study was the absence of a sample size calculation. 
Previous work had groups with unbalanced numbers and smaller sample 
sizes. Also the obese women in these studies had lower BMI, and so were 
not comparable with our population. There was therefore little basis for 
establishing variability, and it was also difficult to estimate likely clinically 
important between-group differences in one or more echocardiographically 
measured parameter. Therefore, we decided upon 2 groups comprising 
equal numbers, and a larger sample size than in previous studies. To some 
extent, the upper limit of the sample size was limited by time constraints. 
In summary, obese pregnant women had similar CO and CI to those with 
normal BMI. The LVM was higher, and SVI was lower, which indicates that 
these parturients may have limited adaptive reserve in clinical situations 
requiring an increase in CO. Obese women had minor decreases in septal 
LV tissue Doppler velocities, but the E/E' average values did not suggest 
clinically significant LV diastolic dysfunction. Further longitudinal studies are 
needed to determine to what extent the changes observed in obese 
parturients are related to obesity alone or to a combination of the pregnant 
state and obesity. Future investigations could establish whether these 
changes contribute to the increased cardiac morbidity in this population, and 
persist postpartum. This could inform the requirement for ongoing monitoring 
of cardiac structure and function, contributing to improved long term 






• Obesity is a rapidly increasing threat to global health, recognised as a 
cardiovascular risk factor; we investigated whether there are cardiac 
structural and functional differences between term healthy and obese 
parturients. 
• Morbidly obese pregnant women have significantly higher left 
ventricular mass and lower stroke volume index than pregnant women 
of normal body weight, and the basal intraventricular septum shows 
signs of remodelling as indicated by lower septal tissue Doppler 
velocities. 
• These structural and functional cardiac differences could limit 
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Tables for publication 
Table 1: Patient characteristics by group 
 Controls (n=40) Obese (n=40) p-value 
Age (years) 28.4 (6.2)  30.4 (4.9)  0.101 


































Haemoglobin(g/dl) 11.4 (1.5) 11.58 (1.4) 0.708 
BMI (kg.m-2) 27.3 (24.2 –29.2) 42.9 (41.3 – 47.1)  
All values are mean (SD) except for BMI, which are median (interquartile 
range) 
Fisher's exact or t-sample t-test 















Mean difference  
(95% CI) 
p-value 
MAP (mmHg) 84 (9.49) 91 (8.42) 7 (3 to 11) < 0.001 
HR (beats/min) 79 (13) 84 (12) 5 (-1 to 10) 0.103 
SV (mL) 59.52 (13.51) 64.38 (9.71) 4.85 (-0.39 to 10.09) 0.069 
SVI (mL.m-2) 34.25 (7.00) 30.14 (4.51) -4.10 (-6.73 to -1.47) 0.003 
CO (mL.min-1) 4740 (1183) 5447 (1048) 707 (210 to1204) 0.006 
CI (L.min-1.m-2) 2729 (623) 2551 (474) -178 (-424 to 69) 0.156 
TVR (dynes.sec.cm-5) 1483 (358) 1367 (217) -116 (-248 to 16) 0.084 
TVRI  
(dynes.sec.cm-5m-2) 
2559 (601) 2927 (519) 367 (117 to 617) 0.005 














(-29.5 to 19.9) 
0.700 
Values are mean (SD), or mean difference (95% CI) 
t-test with unequal variance. After adjustment for multiple comparisons (Bonferroni), 
p<0.005 is statistically significant 
Abbreviations: CI, confidence interval; MAP, mean arterial pressure; HR, heart rate; SV, 
stroke volume; SVI, stroke volume index; CO, cardiac output; CI, cardiac index; TVR, total 












Mean difference  
(95% CI) 
p-value 
IVSd (cm) 0.66 (0.13) 0.82 (0.10) 0.16 (0.11 to 0.22) < 0.001 
LVPWd (cm) 0.95 (0.13) 1.07 (0.16) 0.12 (0.06 to 0.19) < 0.001 
LVIDd (cm) 4.48 (0.36) 4.69 (0.39) 0.20 (0.04 to 0.37) 0.018 
RWT 0.42 (0.06) 0.46 (0.10) 0.04 (0.00 to 0.08) 0.041 
LVM (g) 115 (29) 152 (24) 37 (25 to 49) < 0.001 
LVMI (g.m-2) 66 (15) 71 (12) 5 (1 to 11) 0.0978 
LVM/height (g.m-1) 71 (17)
  
95 (15) 24 (16 to 31) < 0.001 
LVM/height2.7 (g.m2.7) 32 (8) 43 (8) 11 (8 to 15) < 0.001 
FS (%) 35 (5.36) 32 (5.60) -2.71 (-5.15 to -0.27) 0.030 
FAC (%) 53 (6.41) 52 (5.11) -0.44 (-3.02 to 2.15) 0.738 
S' lateral (cm.s-1) 8.95 (1.81) 9.13 (1.95) 0.18 (-0.66 to 1.01) 0.679 
S' septal (cm.s-1) 9.25 (1.64) 8.43 (1.20) -0.83 (-1.47 to -0.18) 0.012 
Values are mean (SD), or mean difference (95% CI) 
t-test with unequal variance. After adjustment for multiple comparisons (Bonferroni), 
p<0.005 is statistically significant.  
Abbreviations: CI, confidence interval; IVSd, interventricular septum in diastole; 
LVPWd, left ventricular posterior wall in diastole; LVIDd, left ventricular internal 
diameter in diastole; RWT, relative wall thickness; LVM, left ventricular mass; LVMI, left 




















 (95% CI)  
p-value 
E/A ratio 1.48 (0.35) 1.33 (0.32) -0.16 (-0.31 to -0.01) 0.042 
DT (ms) 180 (39) 194 (43) 14 (-4 to 33) 0.121 
Septal E' 11.28 (3.18) 9.08 (1.69) -2.20 (-3.34 to -1.06) < 0.001 
Lateral E' 12.78 (3.36) 12.08 (3.56) -0.70 (-2.24 to 0.84) 0.369 
Average E/E' 7.27 (1.68) 7.85 (1.77) 0.58 (-0.19 to 1.35) 0.137 
Septal E'/A' 1.32 (0.44) 1.14 (0.31) -0.18 (-0.35 to -0.01) .039 
Lateral E'/A' 1.70(.73) 1.61(.70) -0.09 (-0.41 to 0.23) .574 
IVRT (ms) 61 (15) 73 (15) 12 (6 to 19) < 0.001 
Values are mean (SD), or mean difference (95% CI) 
t-test with unequal variance. After adjustment for multiple comparisons (Bonferroni), 
p<0.005 is statistically significant 


















Table 5: Right ventricular variables by group  




Mean difference  
(95% CI) 
p-value 
TAPSE (cm) 2.41 (0.44) 2.37 (0.41)  -0.04 (-0.23 to 0.15) 0.698 
S' (cm.s-1) 15.05 (2.92)   14.72 (2.72)  -0.34 (-1.63 to 0.96) 0.606 
RV E'/A' 1.29 (0.32)  1.07 (0.47)  -0.23 (-0.41 to -0.04) 0.016 
Values are mean (SD), or mean difference (95% CI) 
t-test with unequal variance. After adjustment for multiple comparisons (Bonferroni), 
p<0.005 is statistically significant 
Abbreviations: CI, confidence interval; TAPSE, tricuspid annular plane systolic 





























Appendix 1 – HREC Approval letter  
 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
Human Research Ethics Committee 
 Room E52-24 Old Main Building 
 Groote Schuur Hospital  
Observatory 7925 
Telephone [021] 406 6338 • Facsimile [021] 406 6411 
Email: nosi.tsama@uct.ac.za 
Website:   www .health.uct.ac.za/fhs/research/humanethics/forms 
 
21 January 2016 
HREC REF:021/ 2016 
Prof  R Dyer  
D23, Anaesthesia  
NGSH 
Dear Prof Dyer 
PROJECT TITLE: THE IMPACT OF OBESITY ON CARDIAC FUNCTION IN PREGNANCY 
Thank you for submitting your study to the Faculty of Health Sciences Human Research Ethics 
Committee. 
It is a pleasure to inform you that the HREC has formally approved the above-mentioned 
study.  
Approval is granted for one year until the 30'" January 2017. 
The HREC note that recruitment for this study will also occur at Groote Schuur Hospital. 
Please submit a progress form, using the standardised Annual Report Form if the study 
continues beyond the approval period. Please submit a Standard Closure form if the study is 
completed within the approval period. 
(Forms can be found on our website: www .health.uct.ac.za/fhs/ research/humanethics/ 
forms).  
Please quote the HREC REF in all your correspondence. 









PROFESSOR M BLOCKMAN 
CHAIRPERSON, FHS HUMAN RESEARCH ETHICS COMMITTEE 
Federal Wide Assurance Number: FWA00001637. 
Institutional Review Board (IRB) number: IRB00001938 
 
This serves to confirm that the University of Cape Town Human Research Ethics Committee 
complies to the Ethics Standards for Clinical Research with a new drug in patients, based on 
the Medical Research Council (MRC- SA), Food and Drug Administration (FDA-USA), 
International Convention on Harmonisation Good Clinical Practice (ICH GCP) , South Africa n 
Good Clinical Practice Guidelines (DoH 2006), based on the Association of the British 
Pharmaceutical Industry Guidelines (ABP ),and Declaration of Helsinki (2013) guidelines. 
The Human Research Ethics Committee granting this approval is in compliance with the ICH 
Harmonised Tripartite Guidelines E6: Note for Guidance on Good Clinical Practice 


















Appendix 2 - Consent form for control group 
Title of Project:  The Impact of obesity on cardiac function in pregnancy 
Principal Investigator: Prof Robert Dyer 
 
Contact details:  Department of Anaesthesia, University of Cape Town 
                            Groote Schuur Hospital, Anzio Road, Observatory, Cape Town, 7700 
                            Tel:   021 4045001 
 
Participant’s Printed Name:  
We are inviting you to take part in a research study that will be done at Mowbray Maternity 
Hospital during the period January to March 2016.   
The purpose of the study is to find out if an increased weight affects the function of a 
woman’s heart during pregnancy.  
 
It is known that both pregnancy and weight gain may affect the function of a person’s heart. 
We would like to do research to look at how the combination of increased weight and 
pregnancy affect the function of a woman’s heart.   
 
In order to do this we will examine both women of normal and increased weight to be able to 
compare the results.  You are asked to participate in the control group which includes 
women of normal body weight. 
 
We will do this by doing an ultrasound of your heart, also known as an echo.  This is similar 
to the ultrasound we do of your baby during pregnancy.  It takes 20-30 minutes and is safe 
for you and your baby.  We will do this at a time when it will not affect any routine medical 
care. 
 
The echo will give us information about how well your heart is working and coping with 
pregnancy. 
The study may be beneficial to you, because if we find a problem we will inform your 
obstetric doctor and you will receive appropriate treatment of the problem.   
   
When the study is normal it will still be useful and reassuring to have extra information about 
your health status. 
 
You will not be charged or compensated for this study. 
The study is funded by the Department of Anaesthesia. 
 
We will record health information about you that will include your age, gender, ethnicity, 
weight, height, blood pressure, pulse rate and a history of existing disease. We will also 
record how far along your pregnancy is and if you’ve been pregnant before. 
This is information that is usually routinely recorded as part of your pregnancy care. 
You will receive a code number and all information will be stored anonymously in a secured 
area in the Department of Anaesthesia using only this code number.   
The list that matches your name with the code number will be kept in a locked file in the 
Department of Anaesthesia.  
The only reason we need to have your name is in order to be able to inform the obstetric 
doctors if we find any problems that may need treatment.  
   
On completion of this study the data will be presented for review by the University of Cape 
Town and also for possible publication in a medical journal.  In the event of any publication 





We will keep your participation in this research study confidential to the extent permitted by law. 
However, it is possible that other people may become aware of your participation in this study. 
For example, the following people/groups may inspect and copy records pertaining to this 
research in order to ensure that the research complies with ethical and clinical requirements:  
  
• Human Research Ethics Committee 
E 52, Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone:   021 406 6338 
 
Taking part in this study is entirely voluntary.  Giving or withholding consent for this study will 
not affect the quality of health care given to you. If you decide to participate you must sign 
this form to give your consent.  
 
You have the right to ask any questions you may have about this research.  If you have 
questions, complaints or concerns please contact the investigator at the telephone number 
provided above. 
 If you have questions regarding your rights as a research participant or you have concerns or 
general questions about the research, you can also contact the Human Research Ethics 
Committee at the number provided above. 
Your signature below means that you have received and understood the information regarding 
this study, have asked the questions you currently have about the research and those 
questions have been answered. You will receive a copy of the signed and dated form to keep 
for future reference.  
 
 
By signing below, you indicate that you give permission to take part in this research.  
 
     
______________________________         _________ ______ ______________ 




______________________________        _________              ______ ______________ 
Signature of witness 1                                    Date  Printed Name 
 
     
  
_____________________________        _________              ______ ______________ 
Signature of witness 2                                    Date  Printed Name 
 
 
Person Explaining the Research: Your signature below means that you have explained 
the research to the participant/participant representative and have answered any questions 
he/she has about the research. 
 
______________________________      _________        ________________ 
Signature of person who explained this research     Date          Printed Name  
 
 Interpreter (where applicable) 
____________________ ________           ____________________       




Appendix 3 - Consent form for study group (obese pregnant women) 
Title of Project:  The Impact of obesity on cardiac function in pregnancy 
Principal Investigator: Prof Robert Dyer 
 
Contact details:  Department of Anaesthesia, University of Cape Town 
                            Groote Schuur Hospital, Anzio Road, Observatory, Cape Town, 7700 
                            Tel:   021 4045001 
 
Participant’s Printed Name:  
We are inviting you to take part in a research study that will be done at Mowbray Maternity 
Hospital during the period January to March 2016.   
The purpose of the study is to find out if an increased weight affects the function of a 
woman’s heart during pregnancy.  
 
It is known that both pregnancy and weight gain may affect the function of a person’s heart. 
We would like to do research to look at how the combination of increased weight and 
pregnancy affect the function of a woman’s heart.   
 
In order to do this we will examine both women of normal and increased weight to be able to 
compare the results.  You are asked to participate in the group of women with increased 
weight. 
 
We will do this by doing an ultrasound of your heart, also known as an echo.  This is similar 
to the ultrasound we do of your baby during pregnancy.  It takes 20-30 minutes and is safe 
for you and your baby.  We will do this at a time when it will not affect any routine medical 
care. 
 
The echo will give us information about how well your heart is working and coping with 
pregnancy. 
The study may be beneficial to you, because if we find a problem we will inform your 
obstetric doctor and you will receive appropriate treatment of the problem.   
   
When the study is normal it will still be useful and reassuring to have extra information about 
your health status. 
 
You will not be charged or compensated for this study. 
The study is funded by the Department of Anaesthesia. 
 
We will record health information about you that will include your age, gender, ethnicity, 
weight, height, blood pressure, pulse rate and a history of existing disease. We will also 
record how far along your pregnancy is and if you’ve been pregnant before. 
This is information that is usually routinely recorded as part of your pregnancy care. 
You will receive a code number and all information will be stored anonymously in a secured 
area in the Department of Anaesthesia using only this code number.   
The list that matches your name with the code number will be kept in a locked file in the 
Department of Anaesthesia.  
The only reason we need to have your name is in order to be able to inform the obstetric 
doctors if we find any problems that may need treatment.  
   
On completion of this study the data will be presented for review by the University of Cape 
Town and also for possible publication in a medical journal.  In the event of any publication 





We will keep your participation in this research study confidential to the extent permitted by law. 
However, it is possible that other people may become aware of your participation in this study. 
For example, the following people/groups may inspect and copy records pertaining to this 
research in order to ensure that the research complies with ethical and clinical requirements.  
  
• Human Research Ethics Committee 
E 52, Room 24, Old Main Building, Groote Schuur Hospital, Observatory 
Telephone:   021 406 6338 
 
Taking part in this study is entirely voluntary.  Giving or withholding consent for this study will 
not affect the quality of health care given to you. If you decide to participate you must sign 
this form to give your consent.  
 
You have the right to ask any questions you may have about this research.  If you have 
questions, complaints or concerns please contact the investigator at the telephone number 
provided above. 
 If you have questions regarding your rights as a research participant or you have concerns or 
general questions about the research, you can also contact the Human Research Ethics 
Committee at the number provided above. 
Your signature below means that you have received and understood the information regarding 
this study, have asked the questions you currently have about the research and those 
questions have been answered. You will receive a copy of the signed and dated form to keep 
for future reference.  
 
 
By signing below, you indicate that you give permission to take part in this research.  
 
     
______________________________         _________ ______ ______________ 




______________________________        _________              ______ ______________ 
Signature of witness 1                                    Date  Printed Name 
 
     
  
_____________________________        _________              ______ ______________ 




Person Explaining the Research: Your signature below means that you have explained 
the research to the participant/participant representative and have answered any questions 
he/she has about the research. 
 
______________________________      _________        ________________ 
Signature of person who explained this research     Date          Printed Name  
 
 Interpreter (where applicable) 
____________________ ________           ____________________ 




Appendix 4 – STROBE Checklist 





Recommendation                                                                 
 
Comments 
 Title and abstract 1 (a) Indicate the study’s design with a 
commonly used term in the title or the 
abstract 
 See abstract –
p.3-4 
(b) Provide in the abstract an informative and 
balanced summary of what was done and 
what was found 
 
Introduction  
Background/rationale 2  Explain the scientific background and 
rationale for the investigation being reported 
See introduction 
– p.5 
Objectives 3 State specific objectives, including any 
prespecified hypotheses 
p.6 paragraph 2 
Methods  
Study design 4 Present key elements of study design early in 
the paper 
p.7 paragraph 1 
Setting 5 Describe the setting, locations, and relevant 
dates, including periods of recruitment, 
exposure, follow-up, and data collection 
p.7 paragraph 1 
Participants 6 (a) Give the eligibility criteria, and the 
sources and methods of selection of 
participants. Describe methods of follow-up 
p.7 paragraph 1 
(b) For matched studies, give matching 
criteria and number of exposed and 
unexposed  
N/A 
Variables 7 Clearly define all outcomes, exposures, 
predictors, potential confounders, and effect 





8  For each variable of interest, give sources of 
data and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than 
one group:  
Echocardiography 
protocol – p.8 
Bias 9 Describe any efforts to address potential 
sources of bias: 




Study size 10 Explain how the study size was arrived at: 
Prior studies were examined – this further 
discussed in the manuscript 
p.7 paragraph 1 
Quantitative 
variables 
11 Explain how quantitative variables were 
handled in the analyses. If applicable, 
describe which groupings were chosen and 
why.  
p.8 paragraph 1 
Statistical methods 12 (a) Describe all statistical methods, including 
those used to control for confounding  
p.8 paragraph 1 
(b) Describe any methods used to examine 
subgroups and interactions  
N/A 
(c) Explain how missing data were addressed  N/A 
(d) If applicable, explain how loss to follow-
up was addressed  
p.11 paragraph 1 
(e) Describe any sensitivity analyses  N/A 
Results  
Participants 13 (a) Report numbers of individuals at each 
stage of study—eg numbers potentially 
eligible, examined for eligibility, confirmed 
eligible, included in the study, completing 
follow-up, and analysed  
This was a 
straightfoward 
recruitment of 40 




(b) Give reasons for non-participation at each 
stage 
N/A 
(c) Consider use of a flow diagram N/A 
Descriptive data 14 (a) Give characteristics of study participants 
(eg demographic, clinical, social) and 
p.11 paragraph 1 




information on exposures and potential 
confounders  
(b) Indicate number of participants with 
missing data for each variable of interest  
N/A 
(c) Summarise follow-up time (eg, average 
and total amount) 
N/A 
Outcome data 15 Report numbers of outcome events or 
summary measures over time 
N/A 
Main results 16 (a) Give unadjusted estimates and, if 
applicable, confounder-adjusted estimates 
and their precision (eg, 95% confidence 
interval). Make clear which confounders 
were adjusted for and why they were 
included  
N/A 
(b) Report category boundaries when 
continuous variables were categorized  
p.11 paragraph 1, 
BMI limits 
defined 
(c) If relevant, consider translating estimates 
of relative risk into absolute risk for a 
meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of 




Key results 18 Summarise key results with reference to 
study objectives 
p.13 paragraph 1 
Limitations 19 Discuss limitations of the study, taking into 
account sources of potential bias or 
imprecision. Discuss both direction and 
magnitude of any potential bias 
Discussion p.13-
14 
Interpretation 20 Give a cautious overall interpretation of 
results considering objectives, limitations, 
multiplicity of analyses, results from similar 
studies, and other relevant evidence 
Discussion p.13-
14 
Generalisability 21 Discuss the generalisability (external validity) 





Other information  
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if 
applicable, for the original study on which 
the present article is based 
p.2 – Title page, 
funding detailed 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in 
conjunction with this article (freely available on the Web sites of PLoS Medicine at 
http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and 




















Appendix 5 – Instruction to authors, Anesthesia & Analgesia 
Available online from: http://edmgr.ovid.com/aa/accounts/ifauth.htm 
We greatly appreciate your interest in submitting your manuscript 
to Anesthesia & Analgesia or A&A Practice (formerly, A&A Case Reports). 
Our goal is to provide authors with a thorough yet timely review of their 
submissions. All decisions should be completed within 6 weeks, except for 
Review Articles and Special Articles, which may take up to 8 weeks. Authors 
will be updated as to the status of their manuscript and notified if delays 
occur. 
Notice: The Instructions for Authors for Anesthesia & Analgesia and A&A 
Practice (formerly, A&A Case Reports) have been further revised. New 
submissions should be prepared according to the Instructions that follow. 
Failure to do so may result in your submission being returned without review. 
This now current Version 1.3 of the Instructions for Authors replaces 
the earlier Version 1.2. 
In an effort to further promote the existing expanded scope of A&A 
Case Reports—specifically, to publish content of practical appeal to a 
wide audience—the name of this journal will become A&A Practice 
starting in January 2018. 
Additionally, as of January 1, 2018, all Echo Rounds and Echo 
Didactics articles will be published in A&A Practice. 
A&A Practice will remain editorially aligned and operationally 
integrated yet distinct from Anesthesia & Analgesia. 
Mission and Scope 
Anesthesia & Analgesia exists for the benefit of patients under the care of 
health care professionals engaged in the disciplines broadly related to 
anesthesiology, perioperative medicine, critical care medicine, and pain 
medicine. The Journal furthers the care of these patients by reporting the 
fundamental advances in the science of these clinical disciplines and by 
documenting the clinical, laboratory, and administrative advances that guide 
therapy. Anesthesia & Analgesia seeks a balance between definitive clinical 
and management investigations and outstanding basic scientific reports. The 
Journal welcomes original manuscripts containing rigorous design and 
analysis, even if unusual in their approach. 
Authors are encouraged to read this editorial, which describes some of the 
previous changes to the editorial philosophy of Anesthesia & 




a New EQUATOR for Anesthesia & Analgesia. Anesth Analg. 2016;123(1):8-
9. 
Authors are strongly encouraged to adhere to the fundamentals of English 
grammar, syntax, punctuation, and composition. If a paper is poorly written 
and thus difficult to understand, it will likely not receive as favorable a 
review, despite presenting strong science and/or novel information. If 
indicated, please consider using a Language Editing Service (see below) to 
address this issue before your initial submission. 
Anesthesia & Analgesia and A&A Practice Instructions for Authors 
Anesthesia & Analgesia and A&A Practice have specific Instructions for 
Authors for submitting articles, which are found below. We strongly 
encourage all authors to read these instructions completely and carefully, 
and to prepare their manuscripts in accordance with these instructions. 
Articles that are not submitted in accordance with our instructions may 
be returned for revision prior to peer-review or rejected outright. 
Brevity is crucial for a well-written and effective scholarly article. 
Particular attention should thus be paid to the listed word count, 
reference count, and table/figure limits for each article type, both for an 
initial submission and any subsequent revisions. 
The word count, reference count, and table/figure limits will be 
strictly enforced, resulting in a manuscript being returned to the 
author(s) for revision prior to any initial or a subsequent peer-review. 
Occasionally, authors will be asked by the Journal Editorial Board to 
resubmit their work as a different article type. If so, this subsequent 
manuscript will be handled as an entirely new submission, with a 
corresponding new assigned manuscript number. 
Any changes (additions or deletions) of authors will need to be justified 
and clearly communicated. See below, Section 8.A. Role of Authors and 
Contributors. 
Questions? 
If you have a question specifically for the Editor-in-Chief, Dr. Jean-Francois 
Pittet, please email him at jpittet@iars.org, or contact the Deputy Editor-in-
Chief, Dr. Thomas Vetter at thomas.vetter@austin.utexas.edu 
If you have questions about these submission instructions, or the Journal 
peer review process in general, please contact the Editorial 




Manuscripts may only be submitted via the Editorial Manager online 
submission system. Submit your manuscript here. 
If you are new to our journal, our Visual User Guide for Authors will help 
you step-by-step to create an author account and to submit your new 
manuscript via Editorial Manager. 
If you are submitting a revised manuscript, our User Guide for 
Revisions will help you step-by-step to submit your revised manuscript via 
Editorial Manager. 
Download a PDF version of the full Instructions for Authors of Anesthesia & 
Analgesia and A&A Practice 
INSTRUCTIONS FOR AUTHORS 
Section 1A: Anesthesia & Analgesia Article Types 
Section 1B: A&A Practice Article Topics 
Except were specifically noted, instructions in the following Sections 
are the same for both Anesthesia & Analgesia and A&A Practice 
Section 2: Articles at a Glance 
Section 3: Standardized Study Reporting Requirements 
Section 4: Standards for Statistical Methods and Statistical Reporting 
Section 5: Digital Copyright Transfer Agreement 
Section 6: Open Access Option for Publication 
Section 7: Manuscript Preparation Requirements 
Section 8: Editorial, Ethical and Legal Requirements 
Section 9: Common Reasons Your Submission is Returned Without 
Review 
SECTION 1A: ANESTHESIA & ANALGESIA ARTICLE TYPES (Back to 
Contents) 
Original Clinical, Health Services or Education Research Report 





Narrative Review Article 
Systematic Review Articles 
Meta-Analysis 
Editorial 




Letter to the Editor 
Book and Multimedia Reviews 
Meeting Report 
SECTION 1B: A&A PRACTICE ARTICLE TOPICS (Back to Contents) 
In an effort to further promote the existing expanded scope of A&A 
Case Reports—specifically, to publish content of practical appeal to a 
wide audience—the name of this journal will become A&A Practice 
starting in January 2018. 
The scope and content of A&A Practice is intentionally broad. A&A Practice 
publishes short yet informative, peer-reviewed articles that 
simply describe (a) the unique clinical characteristics and/or perioperative, 
critical care, acute pain-related, or chronic pain-related clinical care of one to 
three patients; (b) an important teaching point or novel educational tool; 
or especially (c) an innovative solution to a perioperative, pain, patient 
safety, quality and performance improvement, or global health management 
issue. 
Additionally, as of January 1, 2018, all Echo Rounds and Echo 
Didactics articles will be published in A&A Practice. 
Data collection and analyses are neither expected nor encouraged for 
an A&A Practice submission. 
Submissions to A&A Practice can form the basis for a subsequent, more 
extensive proof-of-concept study or formal research study that is submitted 




A&A Practice will continue to be published only online but it will be indexed 
on PubMed. 
Please note that the previous requirement for conventional written 
patient consent for case reports, as described in Nussmeier N, Saidman 
LJ, Shafer S. A & A Case Reports: A Progress Report and an Update on 
Requirements for Patient Consent. AA Case Rep. 2014 Dec 
1;3(11):141, has been eliminated for submissions from countries like 
the United States where conventional written patient consent is not 
required. 
Nevertheless, case reports for publication by Anesthesia & 
Analgesia originating from the United States must be prepared in 
accordance with the requirements of HIPAA privacy regulations (See below 
Section 7.D. A&A Practice Compliance with HIPAA Privacy Regulations). 
However, regulations outside the United States regarding case reports 
or case series, including a requirement to obtain written patient 
consent, must be followed. 
A&A Practice 
DESCRIPTIONS OF SPECIFIC ARTICLE TYPES 
Anesthesia & Analgesia 
Original Clinical, Health Services, or Educational Research 
Report (Back to Top) 
• An Original Clinical, Health Services, or Educational Research Report 
describes an investigation that focuses on the clinical practice of 
anesthesiology, perioperative medicine, critical care medicine, or pain 
medicine. 
• Original Clinical, Health Services, or Educational Research Reports 
span the spectrum of patient-reported outcomes, clinical 
effectiveness, quality and performance improvement, patient safety, 
health services delivery, dissemination and implementation science, 
health policy, healthcare economics, population health, and education. 
• An Original Clinical, Health Services, or Education Research Report 
includes a Title Page and structured Abstract of no more than 400 
words. 
• A “Key Points” summary is also provided, which describes the 
Question, Findings, and Meaning, each composed of one sentence. 
• These Reports are divided into four sections: Introduction, Methods, 
Results, and Discussion. 
• The Introduction section should be focused and contain no more 
than 400 words. The Introduction succinctly describes, in a series of 




rationale for the study, a priori study aims or objectives, and primary 
study hypothesis, and if appropriate, secondary study hypothesis. 
• The Discussion section should also be focused and contain no more 
than 1,000 words. The Discussion succinctly interprets the primary 
findings of the study and how they relate to previous published 
findings. The limitations of the present study are clearly stated. If 
applicable, future, related research opportunities are briefly proposed. 
• An Original Clinical, Health Services, or Education Research Report 
ranges in total length from 1,500 to 4,000 words (not counting the 
Abstract and references), with no more than 30-40 references and 4-
6 tables and/or figures. Online supplemental material can be 
provided when appropriate. 
• Study Reporting Requirement (EQUATOR) 
• Instructions for Manuscript preparation 
• Instructions for Figure preparation 
• Instructions for Table preparation 
• Instructions for Supplemental Material 
Original Laboratory Research Report (Back to Top) 
• An Original Laboratory Research Report describes an investigation 
that focuses on an aspect of basic science related to anesthesiology, 
perioperative medicine, critical care medicine, or pain medicine. 
• Original Laboratory Research Reports span the spectrum of cell 
biology, immunology, neurobiology, biochemistry, pharmacology, 
microbiology, and genetics. 
• An Original Laboratory Research Report includes a Title Page and 
structured Abstract of no more than 400 words. 
• A “Key Points” summary is also provided, which describes the 
Question, Findings, and Meaning, each composed of one sentence. 
• These Reports are divided into four sections: Introduction, Methods, 
Results, and Discussion. 
• The Introduction section should be focused and contain no more 
than 400 words. The Introduction succinctly describes, in a series of 
short paragraphs, the significance of the topic, pertinent background, 
rationale for the study, a priori study aims or objectives, and primary 
study hypothesis, and if appropriate, secondary study hypothesis. 
• The Discussion section should also be focused and contain no more 
than 1,000 words. The Discussion succinctly interprets the primary 
findings of the study and how they relate to previous published 
findings. The limitations of the present study are clearly stated. If 
applicable, future, related research opportunities are briefly proposed. 
• An Original Laboratory Research Report ranges in total length 
from 1,500 to 4,000 words (not counting the Abstract and 
references), with no more than 30-40 references and 4-6 tables 
and/or figures. Online supplemental material can be provided when 
appropriate. 
• Study Reporting Requirement (EQUATOR) 




• Instructions for Figure preparation 
• Instructions for Table preparation 
• Instructions for Supplemental Material 
Brief Report (Back to Top) 
• A Brief Report describes a clinical or laboratory investigation that 
does not require the breadth of experimentation or documentation 
expected of an Original Research Report. 
• A Brief Report typically involves the analysis of either retrospective or 
preliminary data, thus forming the basis for a subsequent more 
extensive investigation. 
• A Brief Report can also be technical in nature, describing the initial 
use of a new instrumentation or analytic technique. 
• A Brief Report that presents data typically has a smaller sample size 
than an Original Research Report. 
• A Brief Report includes a Title Page and an unstructured Abstract with 
no more than 100 words. Brief Reports contain an Introduction, 
Methods, Results, and a very brief (no more than 1 paragraph long) 
Discussion. 
• A Brief Report contains no more than 1500 words (not counting the 
Abstract and references), with no more than 15 references and 1 
table and/or 1 figure. 
• Study Reporting Requirement (EQUATOR) 
• Instructions for Manuscript preparation 
• Instructions for Figure preparation 
• Instructions for Table preparation 
• Instructions for Supplemental Material 
Narrative and Systematic Review Articles (Back to Top) 
• A Narrative Review Article or Systematic Review 
Article synthesizes previously published material into an integrated 
presentation of the current understanding of a topic. 
• A Narrative Review can be either focused or comprehensive, based 
on its topic and scope. 
• A Narrative Review Article should describe aspects of a topic about 
which scientific and evidence-based consensus exists, as well as 
aspects that remain controversial and are thus topics for ongoing and 
future research. 
• A duly noted and entitled Consensus Practice Guideline is 
considered a specific type of a focused Narrative Review. 
• A duly noted and entitled Statistical Grand Rounds is another 
specific type of a focused Narrative Review of the conventional or 
novel application of contemporary quantitative sciences 
(i.e., statistics, epidemiology, or database management) to issues of 
concern to anesthesia, critical care or pain researchers. Here the 
inclusion of programing code and/or illustrative datasets as online 




• For a Systematic Review, a formal strategy to search and to critically 
evaluate the medical literature should be applied and well-described. 
Such explicit methods are used in a Systematic Review to minimize 
bias in its content and findings. 
• All Review Articles include a Title Page and an unstructured Abstract 
with no more than 400 words. 
• The Introduction section should be focused and contain no more 
than 400 words. 
• The Discussion section should also be focused and contain no more 
than 1,000 words. 
• A Review Article ranges in total length from 1,500 to 5,000 words (not 
counting the Abstract and references), with up to 150 
references and 4-6 tables and/or figures. Online supplemental 
material can be provided when appropriate. 
• Exceptions to these word count, reference count, and table/figure 
limits may be granted at the discretion of the Journal Editorial Board 
for a Consensus Practice Guideline manuscript. 
• Study Reporting Requirement (EQUATOR) 
• Instructions for Manuscript preparation 
• Instructions for Figure preparation 
• Instructions for Table preparation 
• Instructions for Supplemental Material 
Meta-Analysis (Back to Top) 
o A Meta-Analysis uses analytic techniques to combine the 
quantitative results from existing individual studies, which are 
initially identified via a Systematic Review, thereby (a) 
allowing for a more precise estimate of the magnitude of benefit 
or harm of an intervention and/or (b) increasing the applicability 
of the results to a broader range of patients. 
o A Meta-Analysis should not be written and submitted as a 
Systematic Review Article but as a separate submission type. 
o A Meta-Analysis includes a Title Page and structured Abstract 
of no more than 400 words. 
o A “Key Points” summary is also provided, which describes the 
Question, Findings, and Meaning, each composed of one 
sentence 
o These manuscripts are divided into four sections: Introduction, 
Methods, Results, and Discussion. 
o The Introduction section should be focused and contain no 
more than 400 words. 
o The Discussion section should also be focused and contain no 
more than 1,000 words. 
o A Meta-Analysis ranges in total length from 1,500 to 5,000 
words (not counting the Abstract and references), with no 
more than 150 references and 4-6 tables and/or figures. 





o Study Reporting Requirement (EQUATOR) 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Editorial (Back to Top) 
o Editorials are solicited by the Editorial Board 
o An Editorial either (a) provides an editorial perspective on an 
article published in the Journal or (b) expresses the general 
policies or opinions of the Journal Editorial Board. If an Editorial 
is intended to provide an expert perspective on an article or 
topic published in the Journal, it is typically solicited from 
reviewer(s) who provided unusually thoughtful insight during 
the peer-review process, and which the Editors believe should 
be shared with the Journal readership. 
o An Editorial includes a Title but not an Abstract. 
o An Editorial contains no more than 2000 words (not counting 
the references), with no more than 15 references and 
occasionally 1 table and/or 1 figure. 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
The Open Mind (Back to Top) 
o The Open Mind is a unique forum for thoughtful, scholarly, and 
preferably well-referenced perspectives. The Open Mind is 
intended to stimulate lively yet civil discussion. It is a forum for 
(a) challenging myths or dogma and/or (b) proposing new 
approaches or solutions to an important issue facing the 
anesthesiology community. 
o Submissions to The Open Mind include a Title Page but not an 
Abstract. 
o An Open Mind article ranges in total length from 1,500 to 3,000 
words (not counting the references), with up to 20 
references and 2-3 tables and/or figures. 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Special Article (Back to Top) 
o A Special Article is a manuscript that does not fit in any of the 
other article types. They are typically invited by the Editorial 




o Occasionally, authors produce a publishable scholarly text that 
does not fit one of the other article types. After first 
communicating directly with the Journal’s Editor-in-Chief, these 
may be submitted as a Special Article. 
o All Special Articles include a Title Page and an unstructured 
Abstract with no more than 400 words. 
o A Special Article ranges in total length from 1,000 to 5,000 
words (not counting the Abstract and references), with up 
to 150 references and 4-6 tables and/or figures. 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
Letter to the Editor (Back to Top) 
• A Letter to the Editor can offer brief, objective, and constructive 
comments or criticism concerning previously published articles or 
provide other communication of general interest to the readership. 
Such correspondence submissions are not a venue for Case Reports, 
and authors must attest during the submission process, in their cover 
letter, that a case description is not included in their correspondence. 
• A Letter to the Editor should be brief, with no more than 500 words. 
Three or fewer references, a small table or a pertinent illustration may 
be provided. 
• All Letters to the Editor should be submitted via the Anesthesia & 
Analgesia Online Submission and Review System and not via email or 
postal service. 
• Letters are edited by the Correspondence Editor, sometimes 
extensively, to sharpen their focus. A Letter to the Editor may be sent 
for peer review, at the discretion of the Correspondence Editor. 
• A Letter to the Editor that is written in response to a published paper 
must be submitted no later than 3 months after the first of day of the 
month of the original article’s print publication date. 
• Instructions for Manuscript preparation 
Book and Multimedia Reviews (Back to Top) 
o A Book and Multimedia Review reports on a current publication 
about anesthesiology, perioperative medicine, critical care 
medicine, or pain medicine. 
o Publishers interested in having their book or multimedia 
material reviewed by the Journal should first contact our Media 
Reviews editor at: bookreviews@iars.org. 
o A Book Reviews contains no more than 750 words. 
o Instructions for Manuscript preparation 




o A Meeting Report is a scholarly outline of the program and 
content of a scientific meeting. 
o A Meeting Report may be organized temporally (day by day) or 
thematically (topic by topic). 
o Authors interested in submitting meeting reports should first 
contact our Media Reviews editor at bookreviews@iars.org to 
confirm that the meeting is of general interest to the readership. 
o A Meeting report does not have an Abstract and contains no 
more than 1500 words. 
o Instructions for Manuscript preparation 
A&A Practice (Back to Top) 
Please note that when submitting a manuscript to A&A Practice, go 
to http://www.editorialmanager.com/aa/default.aspx and select “A&A 
Practice” as the submission type. 
• An A&A Practice submission includes a Title Page and an 
unstructured Abstract with a maximum of 100 words. 
• If applicable, the title for a case report should include the specific 
words “Case Report.” 
• An A&A Practice submission includes an Introduction; Description of 
the case, project, initiative, setting, or scenario; Discussion; and 
References. 
• An A&A Practice submission contains no more than 1500 words (not 
counting the references), with no more than 15 references. 
• Including pertinent figures, illustrations, tables, and/or supplementary 
digital and video and audio material that expands the reader’s 
understanding of the case report is strongly encouraged. 
o Study Reporting Requirement (EQUATOR) 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
For more information about A&A Practice and to view examples of its 
published manuscripts, visit: http://journals.lww.com/aacr. 
As of January 1, 2018, all Echo Rounds and Echo Didactics articles will 
be published in A&A Practice. Please adhere to the following, otherwise 
unchanged submission details for Echo Rounds and Echo Didactics 
submssions. 
Echo Rounds (Back to Top) 
o Echo Rounds provide a focused discussion of a unique or 
interesting perioperative clinical situation in which ultrasound 




provide succinct teaching points on 
echocardiographic/ultrasound views, techniques or 
calculations. Their teaching content must be supported by the 
current literature or standard reference texts of 
echocardiography, preferably those most accessible to the 
general reader. 
o Authors are advised to examine previously published Echo 
Rounds (either via the Table of Contents or www.anesthesia-
analgesia.org) to avoid submission of previously published 
topics. 
o Echo Rounds should not be construed and presented as "mini 
Case Reports." Therefore, only the most relevant clinical details 
and specific echo findings should be succinctly presented in the 
first one-third of the manuscript. The specific echo findings and 
didactic discussion of the echo topic(s) should comprise the 
subsequent two-thirds of the manuscript. 
o Echo Rounds include a Title Page but not an Abstract. 
o Echo Rounds are short reports with no more than 800 
words (not counting the Abstract and references) and no more 
than 6 references. 
o Echo Rounds should be accompanied by 1-3 
echocardiographic still images and 1-3 video clips with 
legends. The video clips will be available online. The still 
images usually, but not always, correspond to the respective 
video clip(s). Figures and clips should be appropriately labeled 
(e.g., arrows, abbreviations of anatomic structures, etc.). 
Authors may elect to consolidate consecutive time segments 
into a single clip, although adequate viewing time for each 
segment must be provided to clearly illustrate the primary 
findings being discussed in the text. 
o One simple table is also allowed. 
o Study Reporting Requirement (EQUATOR) 
o Echo Rounds Submission Checklist 
o Required HIPAA Waiver 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
o Instructions for Video Preparation 
Echo Didactics (Back to Top) 
o Echo Didactics are solicited submissions presenting a 
practical clinical review of a particular ultrasound topic (e.g., 
important measurements, specific anatomic or physiologic 
evaluation, and current or emerging technologies) related to 





o Echo Didactics include a Title Page but not an Abstract. The 
author should instead provide 3 or 4 bulleted teaching points 
summarizing the most important teaching points. 
o Echo Didactics submissions start with an index case, which is a 
1-2 sentence clinical scenario to preface the content. 
o The main focus of Echo Didactics should be a discussion of the 
most relevant background, the "nuts and bolts" of the 
assessment, measurement, or imaging, and new concepts. 
o Echo Didactics contain no more than 1500 words (not counting 
the bulleted teaching points and references) and no more 
than 10 references. 
o Echo Didactics should include 1 to 3 high-resolution figures and 
1 to 3 video clips, which can be composite videos. Figures and 
clips should be appropriately labeled (e.g., arrows, 
abbreviations of anatomic structures, etc.). Authors may elect 
to consolidate consecutive time segments into a single clip, 
although adequate viewing time for each segment must be 
provided to clearly illustrate the primary findings being 
discussed in the text. 
o One simple table is also allowed. 
o Study Reporting Requirement (EQUATOR) 
o Echo Didactics Checklist 
o Instructions for Manuscript preparation 
o Instructions for Figure preparation 
o Instructions for Table preparation 
o Instructions for Supplemental Material 
SECTION 2: ARTICLES TYPES AT A GLANCE (Back to Contents) 
Particular attention should be paid to the listed word count, reference 
count, and table/figure limits for each article type, both for an initial 
submission and any subsequent revisions. 
These listed word count, reference count, and table/figure limits will be 
strictly enforced, resulting in a manuscript being returned to the 
author(s) for revision prior to any initial or a subsequent peer-review. 
SECTION 3: STANDARDIZED STUDY 
REPORTING REQUIREMENTS (Back to Contents) 
A. Enhancing the Quality of and Transparency of Health Research 
(EQUATOR) Network 
The Enhancing the Quality of and Transparency of Health Research 
(EQUATOR) Network was created to monitor and to propagate the proper 
use of guidelines to improve the quality of scientific publications by promoting 





As advocated by the EQUATOR Network, Anesthesia & 
Analgesia strongly encourages adherence to the applicable 
statement/guidelines and checklist for all submitted research-related 
manuscripts (see Table below). Manuscripts adhering to the applicable 
statement/guidelines and checklist will typically receive a more 
favorable review by the Journal. 
Adhering to the applicable statement/guidelines and checklist promotes 
consistent study design and manuscript content, which are major advantages 
for the Journal’s authors, reviewers, editors, and readers. 
Authors should consult the EQUATOR Network webpage and/or the 
webpage URL or citation listed in the Table below for the most current 
version of the specific, applicable statement or guideline and its checklist. 
• The applicable study checklist should be 
completed and uploaded under the EQUATOR Checklist File 
category at the time of initial manuscript submission via Editorial 
Manager. 
Acronym Full Title of Guideline Webpage URL or Citation 
CONSORT 
Consolidated Standards of 




Transparent Reporting of 




Strengthening the Reporting of 




Preferred Reporting Items for 









Standards for Reporting Qualitative 
Research 
Consolidated Criteria for Reporting 




Consolidated Health Economic 






Standards for Accurate Reporting 






Transparent Reporting of a 
Multivariable Prediction Model for 
Individual Prognosis Or Diagnosis 
STREGA 






Animal Research: Reporting of In 
Vivo Experiments 
http://www.nc3rs.org.uk/arrive-guidelines  
CARE Case Reports http://www.care-statement.org/  
* The main CONSORT Statement is based on the “standard” two-group 
parallel design. However, there are several different types of randomized 
trials, some of which have different designs (e.g., cluster, non-inferiority and 
equivalence, or pragmatic trials), interventions (e.g., herbal medicinal, non-
pharmacological, or acupuncture) and data (e.g., harms), for which specific 
CONSORT Extensions exist. 
B. SPECIFIC STUDY TYPE AND ASSOCIATED PUBLISHED GUIDELINE 
1. Randomized Controlled Trials. Authors reporting the results of 
a randomized controlled trial must follow the CONSORT statement and 
provide a completed CONSORT checklist. Authors must also provide a 
CONSORT flow diagram as Figure 1 of the submitted manuscript. 
Please note that there are CONSORT Extensions for several different types 
of randomized trials, and the most applicable Extension should be followed 
by authors. 
2. Non-Randomized Controlled Trials. Authors reporting the results of 
a non-randomized controlled trial must follow the TREND statement and 
provide a completed TREND checklist. 
3. Observational Studies. Authors reporting the results of a cohort, case-
cohort, nested case-control, case-control, or cross-sectional study (or 
any other type of observational study of human subjects), a case series 
of > 4 patients, or a retrospective data collection study must follow the 
STROBE statement and provide a completed STROBE checklist. 
Authors submitting the results of such a quantitative observational study 
should clearly indicate (a) whether the primary outcome(s) were defined and 
established a prioriat initiation of the study design or were created post hoc 
during data exploration (“data mining”) and accompanying statistical analysis 
and (b) whether subgroup or sensitivity analyses were identified and 
established a priori or post hoc. For studies evaluating a treatment effect, 
indicate whether and how a clinically meaningful effect size was defined, 




For further insights and directions, see Eisenach JC, Kheterpal S, Houle TT. 
Reporting of Observational Research in ANESTHESIOLOGY: The 
Importance of the Analysis Plan. Anesthesiology. 2016;124(5):998-1000. 
For a single case study or small case series of < 3 patients, the STROBE 
statement is not applicable but instead the CARE statement (see below) 
should be followed. 
4. Systematic Review or Meta-analysis. Authors reporting a systematic 
review or meta-analysis of randomized trials or cohort studies must 
follow the PRISMA (previously named QUOROM) Statement and provide a 
completed PRISMA checklist. Authors must also submit a PRISMA flow 
diagram as Figure 1 of the submitted manuscript. 
5. Quality Improvement Research. Authors reporting the results of 
a quality improvement study must follow the SQUIRE 2.0 guidelines and 
provide a completed SQUIRE 2.0 checklist. 
6. Qualitative Research. Authors reporting the results of 
a qualitative study (e.g., in-depth interviews and focus groups) must 
provide a completed SRQR checklist. 
Alternatively, authors reporting the results of a qualitative study can provide 
a completed COREG checklist. 
7. Mixed Methods Research. No definitive guidelines have been created 
for mixed (qualitative/quantitative) research. However, authors 
reporting the results of a mixed methods research study can reference 
the Good Reporting of A Mixed Methods Study (GRAMMS) framework. 
See the following pertinent references: 
Cameron RA, Trudy D, Scott R, Ezaz A, Aswini S. Lessons from the field: 
Applying the Good Reporting of A Mixed Methods Study (GRAMMS) 
framework’. Electronic Journal of Business Research Methods. 2013. 
https://works.bepress.com/roslyn_cameron/131/ 
O'Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in 
health services research. J Health Serv Res Policy. 2008;13(2):92-98. 
O'Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in 
mixed methods studies. BMJ. 2010 Sep 17;341:c4587. 
8. Health Economic Evaluation Research. Authors reporting the results of 
a health economic evaluation research study must follow the CHEERS 
guidelines and provide a completed CHEERS checklist. 
9. Diagnostic Accuracy. Authors reporting a study of the accuracy of a 




STARD checklist. Authors must also provide a STARD flow diagram as 
Figure 1 of the submitted manuscript. 
Alternatively, authors reporting studies of the accuracy of diagnostic tests 
can follow the TRIPOD Statement and provide a completed TRIPOD 
checklist. 
10. Genetic Association Studies. Authors reporting a genetic association 
study must follow the STREGA guidelines and must submit a completed 
STREGA checklist. 
11. Animal Studies. Authors reporting an animal study must follow the 
ARRIVE guidelines and must submit the ARRIVE checklist. 
12. Echo Rounds and Echo Didactics Submission Checklist 
o Authors must submit a completed checklist for an Echo Rounds 
submission Required Echo Rounds Submission Checklist 
o Authors must submit a completed checklist for an Echo 
Didactics submission Required Echo Didactics Submission 
Checklist 
o Echo Rounds or Echo Didactics for publication by A&A 
Practice must be prepared in accordance with the requirements 
of HIPAA privacy regulations (See Section 7.E. A&A Echo 
Rounds and Echo Didactics Compliance with HIPAA 
Privacy Regulations). 
13. Case Reports. Authors reporting the details of a case study of a single 
patient or a case series of <3 patients must follow the CARE Guidelines and 
submit a completed CARE checklist. 
Please note that in the CARE guidelines for Case Reports, item #13 states: 
“Informed Consent: The patient should provide informed consent for this 
case report.” 
However, per the CARE guidelines, for case reports originating from outside 
the United States written patient consent must be obtained. 
Nevertheless, Case Reports for publication by Anesthesia & Analgesia from 
the United States must be prepared in accordance with the requirements of 
HIPAA privacy regulations (See Section 7.D. A&A Practice Compliance 
with HIPAA Privacy Regulations). 
In clinical case reports, authors should state whether they have reported 
serious adverse events to the manufacturer, United States Food and Drug 
Administration (FDA), or other governmental regulatory agency. 
SECTION 4: STANDARDS FOR STATISTICAL 




All authors who are presenting data and data analyses in their 
manuscripts submitted to the Journal are now required to attest via 
Editorial Manager that they have reviewed sections 4A, 4B, 4C and 4D 
located below and have implemented all of the relevant items. 
This should be done preferably before implementing their study data 
collection but certainly as they undertook their statistical analyses and 
prepared their manuscript for initial submission and any requested 
revision(s). 
While Anesthesia & Analgesia has elected not to implement a required 
formal statistical checklist to be completed and submitted by authors, 
adhering to the guidelines below will substantially improve 
chances of publication and avoid delays in the review process. 
Authors may also find this editorial informative: Mascha EJ, Vetter TR. The 
Statistical Checklist and Statistical Review: Two Essential Yet Challenging 
Deliverables. Anesth Analg. 2017 Mar;124(3):719-721. 
A. Statistical Analyses and Methods as Promulgated by the Statistical 
Analyses and Methods in the Published Literature (SAMPL) Guidelines 
As advocated by the EQUATOR Network, Anesthesia & 
Analgesia strongly endorses adherence to the Statistical Analyses and 
Methods in the Published Literature (SAMPL) Guidelines. 
Please see Lang TA, Altman DG. Basic statistical reporting for articles 
published in biomedical journals: The “Statistical Analyses and Methods in 
the Published Literature” or “The SAMPL Guidelines.” Handbook, European 
Association of Science Editors. 2013:23-6. 
The SAMPL Guidelines can be accessed at http://www.equator-
network.org/reporting-guidelines/sampl/. 
BASIC STATISTICAL METHODS AND REPORTING THAT SHOULD BE 
INCLUDED IN ALL QUANTITATIVE MANUSCRIPTS. 
THESE ITEMS ARE COMMONLY MISSING OR DEFICIENT IN 
SUBMITTED MANUSCRIPTS, LEADING TO A LENGTHIER STATISTICAL 
REVIEW. AUTHORS ARE THUS STRONGLY ENCOURAGED TO 
PROACTIVELY ADDRESS ALL OF THESE ISSUES. 
B. For All Studies That Include Data Analysis and/or Estimation: 
1. Primary and secondary outcomes. Primary and secondary 
outcomes must be clearly identified and distinguished in the Abstract, 
Methods, Statistical Methods, Results, and Discussion. The 
designation as primary or secondary outcome should have been 




should be explained. While it is acceptable to present findings not 
anticipated in the study design, these should be clearly identified 
as post hoc observations. 
2. Detailed statistical methods section. The statistical methods 
section needs to closely follow the stated study hypotheses or aims 
(i.e., not a generic list of tests that could apply to most any study and 
its manuscript) and to be sufficiently detailed, including all conducted 
analyses. 
3. Assumptions. Report how the key assumptions of the conducted 
statistical analyses were assessed and confirmed. For example: one-
sided versus two-sided tests of statistical confidence. 
4. Type I error/multiple testing. Explain how a Type I error is protected 
at the given level (e.g., 0.05), if there are multiple primary outcomes or 
multiple testing (e.g., Bonferroni correction or other method). 
Differentiate between overall significance level and the significance 
criterion (P-value cut-point) that are applied to individual comparison 
tests. 
Note: Authors are discouraged from using the argument that adjusting 
for multiple comparisons or multiple testing should not be done 
because it increases the risk of a Type II error (decreases power). 
While it is true that more stringent significance criterion decreases 
power, that is the price of multiple testing, and the sample size needs 
to be increased accordingly. Neglecting to adjust for Type I error can 
lead to extremely high chance of some or many of a study’s 
statistically significant results being false positives. The goal should be 
to focus on key outcomes and exposures in the study design phase. 
5. Justify the sample size. Whether the findings are positive or 
negative, authors should explain how the sample size was derived. 
Authors should also declare the planned (a priori) power or available 
(post-study) power to detect clinically important differences in the 
primary outcome. These are key features of the study design. This 
section should appear immediately after the statistical methods are 
detailed. 
6. For post-study power (not calculated a priori), consider what 
difference would be clinically important, independent of the observed 
results. Post-study power should NOT be based on the observed 
differences, but rather on what the authors (and readers) would 
consider to be clinically important. For an estimation study with no 
statistical comparisons being made (e.g., estimating prevalence or 
diagnostic accuracy), report the planned or available width of the 
confidence interval for primary endpoint. A sample size calculation 
needs to have sufficient information to be reproducible by the reader. 
Note: Requiring authors to report on power to detect clinically 
important differences, as mentioned above, does not take away the 
importance of reporting confidence intervals and interpreting them 




intervals give important information on the available evidence from the 
observed data. Both are important and needed. 
For example, suppose in their design phase, authors had 80% power 
to detect a relative risk of 0.50 or stronger (low power). Then suppose 
the estimated risk ratio (RR) confidence interval from the study was 
0.70 (0.30, 1.9). This study is not conclusively negative since clinically 
important effects are contained within the confidence limits. 
Reporting a priori low power to detect clinically important differences 
(independent of what was actually observed), in addition to the 
observed wide observed confidence interval limits, makes a negative 
conclusion even stronger. 
7. Results section should follow clearly from the statistical 
methods and study objectives. Primary and then secondary aims 
should be addressed in sequence, with clear differentiation. No new 
statistical methods should be introduced in the Results, when they 
have not been provided and referenced earlier in the Methods. 
8. Report treatment effect estimates and variability (standard error or 
confidence interval) of treatment effect estimate at least for the 
primary outcome(s). Confidence intervals and P-values must be 
reported in both the Abstract and Results sections. Also report 
confidence intervals for estimates of incidence, prevalence, when they 
are the primary outcome. Confidence intervals for the primary 
outcomes should be interpreted as the best evidence for where the 
treatment effect or association of interest may fall. Non-significant 
results should be given more weight as conclusively negative when 
the confidence interval does not include what authors or others would 
consider to be clinically important effects. 
9. Similar/equivalent. When conducting tests for superiority, it is not 
appropriate to make claims of groups being “equivalent” or 
“similar.” Non-significant results from superiority tests should 
only make claims of no difference being found. A specific design 
(equivalence study) and tailored analytic methods are required before 
one can make claims of equivalence or similarity. 
10. Baseline comparisons. In a randomized trial, authors should not 
include P-values or related tests comparing randomized groups on 
baseline characteristics. Rather, simply discuss whether clinically 
important differences in the observed numbers are apparent or not. 
Since there is no hypothesis being tested at baseline, the P-values 
are not appropriate. Instead consider assessing balance using 
standardized difference (guidance is that absolute standardized 
difference greater than 0.10 is evidence of imbalance). In statistical 
methods, say what you had planned to do, if anything, if clinical 
imbalances were found at baseline (e.g., include those variables in a 





11. On the other hand, for nonrandomized studies, comparing groups on 
baseline characteristics using statistical tests is important and highly 
recommended. 
12. Conclusions. Conclusions should not go beyond what was tested or 
assessed in the study, and should focus on primary endpoint(s). In 
particular, observational studies—whether retrospective or 
prospective—can only identify association between a variable and an 
outcome. Do not use language that would imply a cause and effect 
relationship (see below). 
C. Additional Elements for Non-Randomized Observational Studies 
Assessing an Association Between Exposure and Outcome. However, 
still Follow Part A and Part B above. 
1. Confounding. Address potential confounding of the relationship of 
interest as thoroughly as possible using multivariable regression, 
propensity score methods, or other methods. Since the goal is 
typically to adjust for as much confounding as possible, it is usually 
neither desired nor ideal to use a so-called parsimonious model when 
considering which variables to adjust for. Adjustment should instead 
be more liberal. When limited adjustment is made, for whatever 
reason, list this as a strong limitation in the Discussion. 
Example: In retrospective database studies, researchers may assess 
the association between an exposure of interest (such as receiving an 
intraoperative blood transfusion or not) and a major postoperative 
complication or event. Since the exposure groups are not randomized, 
they may differ on baseline variables (e.g., age, sex, BMI, 
comorbidities, ASA physical status), variables which themselves may 
be strongly associated with the outcome variable. Researchers will 
want either to control for such variables in a multivariable model when 
assessing the association of interest, or alternatively to use propensity 
score (PS) methods either to match exposed and non-exposed 
patients on the set of potentially confounding variables or alternatively 
to weight by or adjust for the PS. With each method, the goal is to 
reduce confounding. 
2. Causation versus association. Avoid using language suggesting 
causation, such as the exposure "reduced" the outcome, or "effect" of 
the exposure on outcome. Also avoid referring to an independent 
variable as a "risk factor" in an observational study. Instead, state and 
discuss that an "association" was observed between exposure and 
outcome. 
3. When discussing observational results, please be as conservative as 
possible. Many observational studies demonstrate—in essence—that 
sicker patients do worse; this is not a novel finding! Methodologic 
limitations, including the potential for unidentified confounding, should 
be transparently discussed. A statement such as “further research is 




describing how prospective research should be conducted, and what 
the available power to detect a difference might be. 
D. Additional Details for All Studies 
1. P-values. Report all actual P values, not “NS.” P-values should 
usually be rounded to 2 or 3 decimal places. 
2. Say “multivariable” instead of “multivariate” when there are multiple 
independent variables and a single outcome variable. 
3. Tables should include the patient or unit denominator (sample size), 
and should reference the utilized statistical methods in the table 
footnotes. 
4. Tables and figures should stand alone. Tables and figures, along with 
their legends and footnotes, should include enough information about 
what was done statistically to basically stand alone, independent of 
the statistical methods subsection of the manuscript. 
5. Trend. Authors should not say that the nearly statistically significant 
result represents a trend in the data. Neither should authors say “there 
was an effect of X on Y” and then say that it was non-significant—
instead, simply state that it was non-significant or that no association 
was found. 
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An Electronic Copyright Transfer and Disclosure Questionnaire is completed 
by the corresponding author during submission. 
Upon submission, the co-authors are emailed a hyperlink to verify their co-
authorship and complete the electronic Copyright Transfer and Disclosure 
Form within Editorial Manager. 
Questions About the Copyright Transfer and Disclosure Form? 
Please contact our editorial office at editor@anesthesia-analgesia.org 
SECTION 6: OPEN ACCESS OPTION FOR PUBLICATION (Back to 
Contents) 
Authors of accepted peer-reviewed articles have the choice to pay a fee to 
allow perpetual unrestricted online access to their published article to 
readers globally, immediately upon publication. The article processing 
charge for Anesthesia & Analgesia is $3,200 (for CCBY-NC-ND license, 
$4,000 for CCBY) and for A&A Practice is $600 (CCBY-NC-ND only). 
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1. Manuscript, as a single file, consisting of Title Page, Abstract (not 
required for all article types – see Articles At A Glance), Body Text, 
References 
2. Tables (each Table should be a separate .doc file or placed at the end 
of the manuscript file) 
3. Figure Legends (placed consecutively, in numerical order, all on the 
same page) 
4. Figures (each Figure should be uploaded as a separate file) 
5. Appendices (each Appendix should be a separate file) 
Title Page (Back to Top) 
• Article Title 
• First name, middle initial, and last name of each author, with their 
highest academic degree (M.D., Ph.D., etc.), and institutional 
affiliations. 
• Name, mailing address, phone number, and e-mail address of the 
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Health (NIH), Wellcome Trust, Howard Hughes Medical Institute 
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Body (Back to Top) 
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not apply to all article types – See Article Types At A Glance): 
• Textual material (body text, tables, figure legends etc.) should be 
submitted as a .doc or .docx word processing file 
• 12 point Arial or Times New Roman font 
• Introduction (new page). This should rarely exceed one page in 
length. 
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significance, (2) background, (2) rationale, and (3) the study’s 
aims or objectives and if applicable, (5) primary study 
hypothesis, and if appropriate, the secondary study hypothesis. 
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extensive literature review in the Introduction. 
• Methods (new page) 
o A subsection entitled “Statistical Analysis” should appear at the 
end of the Methods section when appropriateA statement that 
the study was approved by the appropriate IRB/Research 




obtained, or that the requirement for written informed consent 
was waived. (See section C Protection of Human Subjects). 
o If applicable, authors should include their clinical trial 
registration number, registry, principle investigator and date of 
registration. (See section G Registration of Clinical Trials) 
o A statement indicating the author has followed the appropriate 
EQUATOR guidelines should be included in the Methods 
section. 
▪ Example: “This manuscript adheres to the applicable 
CONSORT guidelines.” 
o A subsection entitled “Statistical Analysis” should appear at the 
end of the Methods section when appropriate 
• Results (new page) 
• Discussion (new page). Focuses on the findings in the current work 
Acknowledgements (Back to Top) 
For acknowledgement of individuals or organizations, provide complete 
name, degrees, academic rank, department, institutional affiliation, city, 
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• Number references (as superscripts) in the sequence they appear in 
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6, list the first 3 followed by “et al.” 
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• Tables should be uploaded as a separate Word file or presented in 
the main document word file, just after the references. 
• Use a separate page for each table. 
• Individual tables should not exceed two typed pages. If a table 
exceeds two typed pages, start a new table on the subsequent page. 
• For any table that exceeds two typed pages and cannot be divided 
into a new table, the table should be submitted as a supplemental 
digital content file (see formatting requirements for Supplemental 
Digital Content files below). 
• Double-space all table material. 
• Do not submit tables as photographs or pasted images. Tables should 
be black and white only. 
• Number the tables consecutively and cite them consecutively (on first 
instance) in the text. 
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• If you include a block of data, a table, or a figure from another source, 
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• Uploaded as a separate file 
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content file. 
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• Supply a legend for each figure. 
• Group Figure legends on a single page just after the references 
• If a figure has multiple panels (e.g., left, right or A, B, C) please 
specify each panel in the legend. 
• Repeat definitions of any abbreviations used in the legend 
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• Figures should be uploaded as separate .tiff, .jpeg, .pdf or .pptx files. 





• Figures with multiple panels should be condensed into a single file for 
each figure (for example, Figure 1A through 1F should be in one file, 
Figures 2a through 2F should be in a second file, etc.). Each 
individual panel should be labeled with a capital letter. 
• Anesthesia & Analgesia and A&A Practice publish in full color, and 
encourage authors to use color to increase the clarity of figures. 
• Standard colors should be used (black, red, green, blue, cyan, 
magenta, orange, and gray). 
• Avoid colors that are difficult to see on the printed page (e.g., yellow) 
or are visually distracting (e.g., pink). 
• Figure backgrounds and plot areas should be white, not grey. 
• Axis lines and ticks should be black and thick enough to clearly frame 
the image. 
• Axis labels should be large enough to be easily readable and printed 
in black. 
• Number figures consecutively. Supply a brief title for each. Cite figures 
in the text in consecutive, numerical order on first instance. 
• If a figure has already been published, acknowledge the original 
source. You must obtain and submit written permission from the 
copyright holder to reproduce the material when you submit the 
manuscript for review. Unpublished figures require permission of the 
author. Permission is required to reproduce any previously published 
material except for documents or figures in the public domain. See 
Permissions 
• Define all abbreviations used in each figure. Repeat definitions of any 
abbreviations used in subsequent legends. 
Video preparation for Echo Rounds or Echo Didactics (Back to Top) 
The video clip(s) accompanying Echo Rounds or Echo Didactics 
submissions should conform to the following: 
• Formatted in MPEG, QuickTime (MOV), Windows Media Video 
(WMV) or MP4. 
• Play on both Windows and Macintosh platforms. The review process 
will be delayed if the Editorial Office cannot play your video clip. 
• Individual size should not exceed 15 MB. Use video-compression 
software to reduce video size if necessary. 
• Optimal video frame dimensions of 480 x 360 pixels and 640 x 480 
pixels. Videos of 320 x 240 pixels have inadequate resolution for 
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for each segment, and leave a suitable gap between the videos. Use 
appropriate labeling to ensure that the viewer can understand the 
timing of the pathology and events. Labeling can be added with video 




• Authors should complete a video checklist form for each video when 
submitting a revised manuscript. The video checklist form provides the 
information necessary to upload the video on the journal website’s 
video gallery. 
The figure(s) accompanying Echo Rounds or Echo Didactics submissions 
should conform to the following: 
• Formatted in high-resolution JPEG or TIFF formats. 
• Individual size should not exceed 500 KB (to permit adequate 
resolution for printing). 
Supplemental Material (Back to Top) 
• Authors may submit separate supplemental material to enhance their 
article's text and to be considered for online-only posting. 
• Supplemental material may include the following types of content: text 
documents, graphs, tables, figures, audio, and video. 
• Cite all supplemental digital content consecutively in the text. 
• Citations should include the type of material submitted, should be 
clearly labeled, and should include a sequential number (Example 
“Supplemental Figure1”, “Supplemental Table 1”, “Supplemental 
Video 1”). 
• Supplemental Legends should be submitted at the end of the 
manuscript file and should provide a brief description of the 
supplemental content. For example: “Supplemental Table 1: Lists all 
medications used in this study.” 
• Each supplemental digital content file must be composed to 
standalone. For example, tables and figures must include titles, 
legends, and/or footnotes, following journal style, so the viewer can 
fully understand the supplemental content on its own. Production will 
not make any edits to the supplemental files; they will be presented as 
submitted. 
• It is recommended to group multiple supplemental figures/tables into 
one supplemental digital content file when submitting. Each file will be 
given a permanent hyperlink when the Publisher prepares the 
supplemental digital content for posting. To avoid excessive 
hyperlinks in your publication, please group figures/tables. 
• For audio and video files, enter the author name, videographer, 
participants, length (minutes), and size (MB) of file in Editorial 
Manager. Authors should mask patients’ eyes and remove patients’ 
names from supplemental digital content unless they obtain written 
consent from the patients and submit written consent with the 
manuscript. Copyright for video or audio supplemental digital content 
will be required upon acceptance. 
• For a list of acceptable file types and size limits, please review LWW's 





Additional Information (Back to Top) 
1. Units of Measurement 
Use metric units. The units for pressures are mmHg or cmH2O. 
Diagonal slashes are acceptable for simple units, e.g., mg/kg; when 
more than two items are present, negative exponents should be 
used, i.e., ml · kg-1 · min-1 instead of ml/kg/min. 
2. Abbreviations 
Define all abbreviations except those approved by the International 
System of Units for length, mass, time, temperature, amount of 
substance, etc. Do not create new abbreviations for drugs, 
procedures, experimental groups, etc. 
3. Drug Names and Equipment 
Use generic names. If a brand name must be used, insert it in 
parentheses after the generic name. Provide manufacturer's name, 
city, state, and country. Be careful about the use of trademarked 
terms (e.g., ThrombelastographyTM, TEGTM, etc.). 
4. Statistical Analysis 
Detailed statistical methodology must be reported. Describe 
randomization procedures and the specific tests used to examine 
each part of the results; do not simply list a series of tests. Care 
should be taken with respect to a) parametric vs. nonparametric data, 
b) corrections for multiple comparisons, and c) rounding errors 
(summary statistics should not contain more significant digits than the 
original data). Median range (or percentiles) is preferred for 
nonparametric data. 
5. Patient Identification 
Do not use patients' names, initials, or hospital numbers. An individual 
(other than an author) must not be recognizable in photographs 
unless written consent of the subject has been obtained and is 
provided at the time of submission. 
Permissions (Back to Top) 
Authors must submit written permission from the copyright owner (usually the 
publisher) to use direct quotations, tables, or illustrations that have appeared 
in copyright form elsewhere, along with complete details about the source. 
Any permission fees that might be required by the copyright owner are the 
responsibility of the authors requesting use of the borrowed material, not the 




and/or rights to use content from Anesthesia & Analgesia, access 
the Copyright Clearance Center) and enter Anesthesia & Analgesia in the 
‘Get Permissions’ field in the upper-right corner. Please note: Permission will 
not be granted to adapt figures that have been previously published 
in Anesthesia & Analgesia. Contact the Editorial Office at editor@anesthesia-
analgesia.org for further information. 
Language Editing Services (Back to Top) 
Articles submitted to the Journal must be written with a solid basis of English 
language. Awkward or non-intelligible English grammar and syntax can 
adversely affect the review process and this likelihood of acceptance of a 
manuscript. Authors whose native language is not English should thus 
strongly consider having their manuscript copy-edited by a native 
English language medical/technical writer prior to initial submission. 
If you need assistance in preparing a manuscript for submission, our 
publisher, Wolters Kluwer, in partnership with Editage, offers a range of 
editorial services for a fee, including: 
• Premium Editing: Intensive language and structural editing of 
academic papers to improve the clarity and impact of your manuscript. 
• Advanced Editing: A complete language, grammar, and terminology 
check to give you a publication-ready manuscript. 
• Translation with Editing: Write your paper in your native language and 
Wolters Kluwer Author Services will translate it into English, as well as 
edit it to ensure that it meets international publication standards. 
• Plagiarism Check: Helps ensure that your manuscript contains no 
instances of unintentional plagiarism. 
• Artwork Preparation: Save precious time and effort by ensuring that 
your artwork is viewed favorably by the journal without you having to 
incur the additional cost of purchasing special graphics software. 
For more information regarding Wolters Kluwer Author Services and to 
receive a quote for your manuscript, please 
visit wkauthorservices.editage.com. Please note that use of Wolters Kluwer 
Author Services is at the discretion and cost of the authors and does not in 
any way imply a guarantee, or even a likelihood, of acceptance of your 
manuscript in Anesthesia & Analgesia or A&A Practice. 
Section 8: EDITORIAL, ETHICAL AND LEGAL REQUIREMENTS (Back to 
Contents) 
Anesthesia & Analgesia and A&A Practice follow the International Committee 
of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, 




All authors submitting a manuscript to Anesthesia & 
Analgesia and A&A Practice are required to understand and to adhere 
to the material below. 
A. Role of Authors and Contributors 
Anesthesia & Analgesia and A&A Practice adhere to the 
ICMJE recommendations for defining the role of authors and non-author 
contributors 
Anesthesia & Analgesia and A&A Practice therefore defines manuscript 
authorship as meeting the following 4 criteria: 
1. Substantial contributions to the conception or design of the work; or the 
acquisition, analysis, or interpretation of data for the work; AND 
2. Drafting the work or revising it critically for important intellectual content; 
AND 
3. Final approval of the version to be published; AND 
4. Agreement to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. 
Those individuals who do not meet all four criteria should be acknowledged 
as “non-author contributors” on the Title Page of the submission, which will 
be printed in an Acknowledgement section of the published paper. 
Each manuscript must have a “Corresponding Author.” The corresponding 
author serves as the primary contact during the submission and review 
process on behalf of all co-authors. Upon submission, the corresponding 
author is required to attest to the validity and legitimacy of the data and 
interpretation. The corresponding author is responsible for ensuring that all 
authors have reviewed the manuscript and have completed the conflict of 
interest disclosures. If the manuscript is accepted, the corresponding author 
is responsible for reviewing the proof. 
If during the manuscript review process or with a complete 
resubmission, an initial author is deleted or another author is added, 
this change must be justified in the revision cover letter. The deleted or 
added author must be formally notified in writing, with a copy of this 
co-author correspondence sent to the Journal Editorial Office. 
Upon acceptance, the Editorial Office will also require a 
completed Authorship Change Verification form, finalizing the agreed 
upon authorship order for the accepted submission from each author 




B. Author Conflict of Interest 
Anesthesia & Analgesia A&A Practice endorse the ICMJE recommendations 
for defining the role of authors’ conflict of interest. 
• Anesthesia & Analgesia A&A Practice holds that a conflict of interest 
exists when professional judgment concerning the primary interest, 
including patients’ welfare or the validity of research, may be 
influenced by a secondary interest like financial gain. Perceptions of 
conflict of interest are as important as actual conflicts of interest. 
• Authors therefore must define all funding sources supporting their 
work. This includes departmental, hospital, or institutional funds. The 
authors must disclose commercial associations that might pose a 
conflict of interest in connection with the work submitted. Financial 
relationships such as employment, consultancies, stock ownership or 
options, honoraria, patents, and paid expert testimony must also be 
reported. 
C. Protection of Human Subjects 
Research is a systematic investigation for the creation of generalizable 
knowledge. Any investigation submitted for publication demonstrates intent 
to create generalizable knowledge, and thus constitutes research. 
The name of the institutional research ethical review and oversight 
committee varies with country and local custom. In the United States, this 
committee is called the Institutional Review Board (IRB). Other countries 
may use other terms (e.g., “Research Ethics Committee”) for their research 
ethical review committee. “Institutional Review Board” is used here 
generically to refer to the local board that reviews the ethical treatment of 
human subjects and grants institutional approval for the study. 
• Regardless of the country of origin, all clinical investigators 
undertaking human subjects research must abide by the “Ethical 
Principles for Medical Research Involving Human Subjects” outlined in 
the Declaration of Helsinki, and adopted in October 2000 by the World 
Medical Association. 
Clinical studies not meeting the Declaration of Helsinki criteria will not be 
considered for publication. If published research is subsequently found to be 
noncompliant, it will be retracted. 
• On the basis of the Declaration of Helsinki, Anesthesia & 
Analgesia requires that all manuscripts reporting clinical research 
state in the first paragraph of the Methods section that: 





2. Written informed consent was obtained from all subjects, a legal 
surrogate, the parents or legal guardians for minor subjects, or that the 
requirement for written informed consent was waived by the Institutional 
Review Board (IRB). 
The Editors of Anesthesia & Analgesia may question the authors about the 
details of the IRB review, informed consent forms, or the consent process. 
On occasion, the Editor-in-Chief may request a copy of the approved IRB 
application from the author. Lack of appropriate consent or its documentation 
will be grounds for rejection or subsequent retraction. 
• Patients also have a right to privacy regarding their protected health 
information (PHI). Access to their protected health information (PHI) 
should not occur without their written authorization of use or 
disclosure of PHI for the explicit purposes of (a) research or (b) a case 
report (N = 1) or case series (N < 3). Under certain circumstances, the 
requirement for patient written authorization may be waived by the 
Institutional Review Board (IRB). 
D. A&A Practice Compliance with United States HIPAA Privacy 
Regulations 
A patient’s protected health information (PHI) can be viewed and used in a 
clinical setting by those who are assisting with or learning how to provide 
health care to patients. For example, a patient’s PHI can be used internally 
for grand rounds or quality improvement and patient safety projects and 
related presentations. 
However, the circumstances are different in the United States if the PHI is to 
be shared outside one’s own HIPAA-covered entity’s clinical education 
setting. 
When making presentations outside one’s HIPAA-covered entity’s clinical 
education setting or when preparing a case report or case series (with an N ≤ 
3) for publication, the researcher or educator must adhere to two 
requirements: 
1. One must remove all PHI data elements from the patient information 
before using it. If all of the 18 PHI data elements, found 
at http://www.hhs.gov/hipaa/for-professionals/privacy/special-
topics/de-identification/index.html#standard, are removed from the 
presentation or a case report or case series (with an N ≤ 3) for 
publication, then the information is de-identified data and contains no 
PHI. 
Take special note that one these 18 PHI data elements includes: “Any 
other unique identifying number, characteristic, or code.” This 
scenario includes a clinical case so unique that individuals with 




situation, a written authorization must be obtained for disclosure of the 
PHI in a case report or case series (with an N ≤ 3) for publication. 
2. If a clinician, educator, or researcher must include any PHI data 
elements as part of the activity (including the above “other unique 
identifying characteristic”), then the second requirement also applies. 
The patient must authorize the use of their PHI by signing a written 
HIPAA-compliant authorization, which prescribes how their PHI will be 
used for a specific purpose. Examples of situations for which patient 
authorization is required include preparation of a case report or case 
series (with an N ≤ 3) for publication, a lecture to national or 
international professional meeting, and presentation to a class or 
seminar outside the covered entity’s clinical education setting. 
A case report or retrospective chart review with three (3) or fewer patients 
(N < 3), which is not presented as a systematic investigation that is designed 
to contribute to generalizable knowledge, is not considered research. Such 
efforts do not require Institutional Review Board (IRB) approval, if originating 
from the United States. 
A&A Practice therefore, for submissions originating from the United States, 
(a) does not require IRB approval but (b) does require that written HIPAA 
authorization (permission) is obtained from the patient (or deceased patient’s 
relative) for submission of a Clinical Case Report or Case Series for potential 
publication. Authors should use their own institutional HIPAA 
Authorization form for this purpose. 
This authorization must be obtained before submission of the manuscript, 
and the authors must state this authorization was obtained at the end of the 
introduction section. If photographs of the patient, in any form, are used, a 
specific signed permission from the patient must be obtained, and a copy of 
this signed permission be submitted with the manuscript. Failure to comply 
with these requirements will result in rejection of the manuscript. 
As noted above, regulations outside the United States regarding case reports 
or case series, including a requirement to obtain IRB or Research Ethics 
Committee approval and written patient consent, must be followed. 
E. A&A Practice Echo Rounds and Echo Didactics Compliance with 
HIPAA Privacy Regulations 
A patient’s protected health information (PHI) can be viewed and used in a 
clinical setting by those who are assisting with or learning how to provide 
health care to patients. For example, a patient’s PHI can be used internally 
for grand rounds or quality improvement and patient safety projects and 
related presentations. 
The circumstances are different if the PHI is to be shared outside one’s own 




When making presentations outside one’s HIPAA-covered entity’s clinical 
education setting or when preparing a case report (N = 1) (which includes an 
Anesthesia & Analgesia Echo Rounds) or case series (with an N < 3) for 
publication, the researcher or educator must adhere to two requirements: 
1. One must remove all PHI data elements from the patient information 
before using it. If all of the 18 PHI data elements, found 
at http://www.hhs.gov/hipaa/for-professionals/privacy/special-
topics/de-identification/index.html#standard, are removed from the 
presentation or a case report or case series (with an N ≤ 3) for 
publication, then the information is de-identified data and contains no 
PHI. 
Take special note that one these 18 PHI data elements includes: “Any 
other unique identifying number, characteristic, or code.” This 
scenario includes a clinical case so unique that individuals with 
personal knowledge of the incident could identify the patient. In this 
situation, an authorization must be obtained for disclosure of the PHI 
in a case report or case series (with an N ≤ 3) for publication. 
2. If a clinician, educator, or researcher must include any PHI data 
elements as part of the activity, then the second requirement applies. 
The patient must authorize the use of their PHI by signing a written 
HIPAA-compliant authorization, which prescribes how their PHI will be 
used for a specific purpose. Examples of situations for which patient 
authorization is required include preparation of a case report or case 
series (with an N ≤ 3) for publication, a lecture to national or 
international professional meeting, and presentation to a class or 
seminar outside the covered entity’s clinical education setting. 
A case report or retrospective chart review with three (3) or fewer patients (N 
< 3), which is not presented as a systematic investigation that is designed to 
contribute to generalizable knowledge, is not considered research. Such 
efforts do not require Institutional Review Board (IRB) approval. 
As with Case Reports (see Section 7.D above), Anesthesia & 
Analgesia therefore (a) does not require IRB approval but (b) does require 
that a HIPAA-compliant written authorization of use or disclosure of PHI, for 
the explicit purposes of the Echo Rounds manuscript, is obtained from the 
patient (or a deceased patient’s relative) for submission of an Echo Rounds 
for potential publication. This written authorization of use or disclosure of PHI 
must be obtained before submission of the manuscript. The author(s) must 
state they obtained this written authorization of use or disclosure of PHI in 
their submission cover letter. Failure to comply with these requirements will 







F. Investigational Drugs 
The Editorial Board of Anesthesia & Analgesia may exercise judgment about 
the ethics of a clinical trial involving investigational drugs that differs from the 
view of the investigators’ Institutional Review Board. This situation most 
frequently occurs in studies involving neuraxial or perineural drug 
administration; drug studies in children; and nonconformity in dose, route, or 
indication (“off-label” use). 
• Studies using drugs injected into the neuraxial (caudal, intrathecal, or 
epidural) or perineural space must meet at least one of three criteria: 
1. The drug is approved for neuraxial or perineural administration by the 
United States (US) Food and Drug Administration (FDA) or the equivalent 
regulatory agency for the country in which the study took place. 
2. The drug is not approved for neuraxial or perineural use, but it is widely 
used and accepted for neuraxial (e.g., fentanyl) or perineural administration. 
The publication of dosing guidelines in multiple textbooks represents a 
reasonable demonstration that a drug is widely used and accepted for 
neuraxial or perineural administration. 
3. The study is performed under an Investigational New Drug (IND) or 
Biologics License Application (BLA) application approved by the US FDA or 
the equivalent agency in the investigator’s country. 
• Anesthesia & Analgesia is committed to expanding knowledge of the 
clinical pharmacology of drugs in children. However, studying drugs in 
children when there is no pediatric indication poses ethical concerns. 
Therefore, studies of drugs in children must meet at least one of three 
criteria: 
1. The drug is approved for pediatric administration by the US FDA or an 
equivalent regulatory agency. 
2. The drug is not approved for use in children but is widely used and 
accepted for pediatric administration. A reasonable demonstration that the 
drug is clinically accepted for use in children is when the administration in the 
study is consistent with the route, dose, and indication reported in multiple 
textbooks. 
3. The study is done under an IND application approved by the US FDA or 
the equivalent agency in the investigator’s country. Investigators in the 
United States are directed to the FDA website for further information on 




Anesthesia & Analgesia will not publish a paper describing a retrospective 
assessment involving pediatric drug administration, if the treatment would be 
considered inappropriate or unethical in a prospective trial. 
• Drugs are commonly used off-label in clinical trials, and the practice is 
generally acceptable. However, the Editorial Board of Anesthesia & 
Analgesia reserves the right not to review a manuscript describing off-
label administration of a drug if the Editorial Board believes the study 
posed unacceptable risk to subjects. To preclude such a 
determination, investigators are encouraged to obtain an Investigator 
IND from the US FDA or an equivalent agency in their country before 
initiating studies involving off-label drug administration. 
G. Registration of Clinical Trials 
All clinical trials involving assignment of patients to treatment groups 
must be registered prior to the start of the trial and any patient 
enrollment is undertaken. 
The registry, registration number, principal investigator's name, and date of 
registration must be stated in the first paragraph of the Methods section of 
the manuscript. 
Authors must state in the Methods section of their manuscript that 
registration of their clinical trial occurred prior to the start of the trial 
and any patient enrollment undertaken. 
A number of registries have been approved by the International Committee 
of Medical Journal Editors (http://www.icmje.org/about-icmje/faqs/clinical-
trials-registration/), including http://www.clinicaltrials.gov (the most commonly 
used registry in the United 
States), http://isrctn.org, http://www.umin.ac.jp/ctr/index/htm, http://www.anzc
tr.org.au, and http://www.trialregister.nl. Submissions that have registered 
with the European Clinical Trials Database, EudraCT 
(https://eudract.ema.europa.eu/) meet this requirement. 
H. Protection of Animal Subjects 
Manuscripts describing investigations performed in vertebrate animals must 
explicitly state that the study was approved by the authors’ Institutional 
Review Board for animal research (e.g., Institutional Animal Care and Use 
Committee, IACUC). The Journal expects humane and ethical treatment of 
all experimental animals, and requires that the study has been conducted in 
a manner that does not inflict unnecessary pain or discomfort upon the 
animals, as outlined by the United States Public Health Service Policy on 
Humane Care and Use of Laboratory Animals and the Guide for the Care 
and Use of Laboratory Animals (1996), prepared by the National Academy of 
Sciences’ Institute for Laboratory Animal Research. A statement to this effect 





Plagiarism is the use of previously published material without attribution. The 
Editorial Office screens all submitted manuscripts for plagiarism, using 
a sophisticated software program, prior to peer review. This software 
screening process identifies passages of text that have been previously 
published and generates a qualitative/quantitative report. This report is 
reviewed by the Journal Editorial Board and its support staff. 
Text copied from previously published work is interpreted using the following 
taxonomy: 
• Intellectual theft is misrepresentation by an author that words and 
ideas previously published by another author represent the plagiarist’s 
own scholarship. It is the most serious form of plagiarism. Intellectual 
theft identified during screening results in immediate rejection of the 
manuscript and a request for an explanation from the author. 
• Intellectual sloth is the use of the words of another author to avoid the 
effort of writing new text. It commonly occurs when descriptions of 
research methodology are taken from prior publications. It is less 
serious than intellectual theft, because the text is generic and of no 
particular value. Submissions containing intellectual sloth are typically 
returned to the authors with a request that the copied text either 
correctly cite the original author or be rewritten in the authors’ own 
words. 
• Plagiarism for scientific English occurs when authors uncomfortable 
using scientific English compose their manuscripts as a patchwork of 
previously published sentences and paragraphs. Papers constructed 
in such a manner are rejected outright, primarily because patchwork 
plagiarism suggests that the authors may not understand the text they 
have submitted for publication. 
• Technical plagiarism is the use of verbatim text not identified as taken 
verbatim, but simply referenced to the original source. The offense is 
a technical one, and authors are simply asked to correct it prior to 
peer review. 
• “Self-plagiarism” occurs when an author uses his or her verbatim 
words from a previous manuscript in a new submission. Provided the 
authors are not engaged in duplicate publication, the Journal does not 
view “self-plagiarism” as misconduct. Authors are permitted to reuse 
their own words, and are encouraged to do so when describing 
identical research methods in multiple papers. 
J. Duplicate Submission or Duplicate Publication 
• Duplicate submission is concurrent submission of a nearly identical 
manuscript to two journals. It is improper for authors to submit a 
manuscript describing essentially the same research simultaneously 
to more than one peer-reviewed research journal. Authors should not 




simultaneously to more than one journal. Duplicate submissions 
identified during peer review will be immediately rejected. Duplicate 
submissions that are discovered after publication in the Journal will be 
retracted. 
• Duplicate publication is prior publication of a manuscript with 
considerable content overlap, particularly in the research results, by 
the same author or co-authors. Prior publication may be in the same 
language or it may be a translation (usually from the author’s native 
language to English). Submitted manuscripts must not have been 
published elsewhere, in whole or in part, on paper or electronically. 
This includes personal, departmental, educational, or other Internet 
sites. This does not apply to abstracts of scientific meetings or to 
lecture handouts (e.g., IARS Annual Meeting, ASA Annual 
Meeting). Anesthesia & Analgesia requests that authors inform the 
Journal when results of a submitted manuscript have been previously 
presented or published in any venue. If a manuscript has been 
published previously, the submission to Anesthesia & 
Analgesia and A&A Practice will be rejected unless it has already 
been published by the Journal, in which case it will be retracted. 
K. Scientific Misconduct 
When Anesthesia & Analgesia has concerns or receives allegations of 
scientific misconduct, Anesthesia & Analgesia reserves the right to proceed 
according to the procedures described below. 
Anesthesia & Analgesia recognize its responsibility to appropriately address 
concerns allegations of misconduct. Examples of misconduct include: fraud, 
data fabrication, data falsification, plagiarism, improper designations of 
authorship, duplicate publication, misappropriation of others' research, failure 
to disclose conflict(s) of interest, and failure to comply with applicable 
legislative or regulatory requirements. Misconduct also includes failure to 
comply with any rules, policies, or procedures implemented by Anesthesia & 
Analgesia. 
In general, Anesthesia & Analgesia follows the recommendations of the 
Committee on Publication Ethics (COPE) when working to address 
allegations of misconduct. When a concern or allegation is raised involved 
parties generally will be contacted to provide an explanation of the situation. 
As needed, Anesthesia & Analgesia may also contact the institution at which 
the study was conducted and any other involved journals. Anesthesia & 
Analgesia will attempt to determine whether there was misconduct and the 
Editor-in-Chief will respond with an appropriate action. Examples of action 
include: 
• Sending a letter of explanation only to the person(s) involved or 




• Sending a letter of reprimand to the same person(s), warning of the 
consequences of future, similar instances. 
• Sending a letter to the relevant head of the educational institution 
and/or financial sponsor of the person(s) involved, expressing the 
concerns and information collected. 
• Publishing in Anesthesia & Analgesiaa notice of duplicate publication, 
"salami" publishing, plagiarism, or other misconduct, if clearly 
documented. In cases of ghostwritten manuscripts, the notice may 
include the names of the responsible companies as well as the 
submitting author(s). 
• Providing specific names to the media and/or government 
organizations, if contacted regarding the misconduct. 
• Formally withdrawing or retracting the article from Anesthesia & 
Analgesia, and informing readers and indexing authorities 
• Banning an author or authors from publishing any manuscript in 
Anesthesiology for a specified time period, with notice to the author(s) 
institution. 
Section 9: Common Reasons Why a Submission is Returned Without 
Review (Back to Contents) 
1. Incomplete Title Page - e.g., missing conflict of interest statement for 
each author or incomplete author information 
2. Abstract is missing in the Word file or not properly structured. 
3. Missing page numbers 
4. Entire manuscript is not double-spaced 
5. Methods section does not begin with an IRB approval and written 
patient consent statement. 
6. Clinical Case Report does not specifically state at the end of the 
introduction section that or "a written HIPAA authorization to 
use/disclose existing protected health information" (required in the 
United States") or "written patent consent" (if required outside the 
United States) was obtained. 
7. References do not adhere to AMA style (see above). 
8. The above noted word count, reference count, and table/figure count 
limits are not followed for a specific article type. 
 
 
 
